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Noncritical size bone defects may heal without planned surgical reconstruction and 
secondary surgery. Critical-size bone defects do not spontaneously heal and are a major 
clinical and socio-economic problem. The most common regenerative procedure for 
critical-sized bone defects is placing bone grafts to aid the healing [1,2]. The exact 
minimum dimensions for a critical size defect are not clear, but in long bones, it is defined 
as a defect with a length that exceeds the diameter of the affected bone by 2 to 2.5 
times [3] or ‘the smallest osseous defect that will not spontaneously heal during the 
lifespan of the patient or animal’ [2]. Such critical-size defects can be caused by trauma, 
infections requiring debridement of the bone, resection of bone tumors, and skeletal 
diseases, and are sometimes accompanied by pain. Due to multiple operations and 
longer hospitalization, the management of such large bone defects have a negative 
impact on the patients’ quality of life and offers a significant disease burden. Therefore, 
other options focused on rapid healing of these defects are needed.
Bone
Bone is a hard, calcified connective tissue with many essential functions, such as 
support, protection of the internal organs and marrow cavities, and calcium and 
phosphate storage [4]. It is continuously remodeled and, when broken (non-critical 
size defect), can repair itself due to its good intrinsic healing capacity. This healing 
starts with hematoma formation, which is accompanied by an inflammatory response. 
During this response, mesenchymal stem cells are recruited, and blood vessel 
formation is stimulated, through the local production of cytokines and growth factors 
(e.g., interleukins, tumor necrosis factor-alfa (TNF-α), bone morphogenetic proteins 
(BMPs), and vascular endothelial growth factor (VEGF)). A callus is formed to stabilize 
the fracture, which generally first undergoes chondrogenesis and subsequently 
calcifies before being remodeled into lamellar bone [5,6].
Bone remodeling
Continuous remodeling of healthy bone (bone metabolism) is carried out by 
osteoclasts and osteoblasts and occurs in three stages: resorption, reversal, and 
formation. In the resorption stage, preosteoclasts are attracted and mature into 
osteoclasts on the bone surface, where they resorb part of the bone [7]. Osteoclasts 
are multinucleated cells derived from the hematopoietic lineage and resorb bone 
in two steps: First, the inorganic components of the bone are dissolved through the 
formation of a sealing zone and lowering of the pH, followed by the digestion and 
degradation of the organic components such as collagen by proteolytic enzymes [8]. 
In the reversal stage, the resorption processes are coupled to the formation processes. 
During this coupling, osteoclasts and osteoblasts influence each other by sending 
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General Introduction
coupling signals [9]. Bone lining cells prepare the surface of the resorbed pit for bone 
formation and give signals for the migration and differentiation of osteoblasts [10]. 
In the last stage, the formation stage, osteoblast produce new bone. Osteoblasts are 
mononuclear cells derived from mesenchymal stem cells and lay down the new bone 
in the resorbed pits. They synthesize the organic matrix, the osteoid, which is then 
mineralized [11]. Osteoblasts frequently are incorporated into the matrix, where they 
differentiate into osteocytes – by far the most abundant cell type in bone –, they 
become lining cells, or they undergo apoptosis. The remodeling process ends with 
bone lining cells covering the surface [4,7].
Autologous bone grafts
Despite the functional intrinsic healing capacity of bone, the reconstruction of critical-
size bone defects, as a consequence of injury or cancer, remains challenging. The 
‘golden standard’ to treat these large defects is an autologous bone graft [12]. Such 
grafts are considered the ‘golden standard’ since it provides an osteoconductive 
as well as osteoinductive environment due to the presence of both living cells and 
growth factors [13]. Autologous bone grafts are harvested from the patient, often from 
the iliac crest, the cranium, or from the symphysis of the chin or ascending ramus in 
the case of orofacial defects. Such grafts are used in several fields such as dentistry, 
oral and maxillofacial surgery, and orthopedic surgery, to stimulate the formation of 
new bone. However, this treatment has its limitations, i.e. limited volume of available 
tissue graft, extended anesthesia time, additional surgical resources, and donor site 
morbidity. Also, poor results have been reported [14]. Alternative approaches for bone 
reconstruction, such as bone tissue engineering, could overcome these limitations
Bone tissue engineering
To stimulate bone formation, bone tissue engineering approaches combine the use of 
scaffolds, cells, and physical and/or chemical stimuli [5]. Chemical stimuli include bone 
morphogenetic protein-2 (BMP-2) [15,16], vascular endothelial growth factor (VEGF) 
[17] and 1,25(OH)2 vitamin D3 (vitD3) [18–20]. Scaffolds for bone tissue engineering can 
be comprised of many materials and preferably degrade at the same speed as the new 
bone is formed, as scaffolds are not intended to be permanent implants [21]. Ceramics 
are a class of biomaterials that are often used in bone tissue engineering since the 
crystals in calcium phosphate (CaP)-containing scaffolds resemble the hydroxyapatite 
(HA) in natural bone and such materials are osteoconductive [5]. In addition, most 
forms of CaP dissolve chemically or are resorbed by osteoclasts, making these scaffolds 
bioresorbable [22]. Subsequently, the CaP can re-precipitate, thereby transforming 
the scaffold surface, which stimulates the formation of bone [23,24]. Fabrication of 
CaP-containing scaffolds can be performed in several ways, e.g. gel casting [25,26] 
1
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Chapter 1
foaming [27,28] , freeze casting [29,30] and coatings [31,32]. The achieved fit of scaffolds 
produced with these fabrication methods is not always precise, leaving lacunae in 
the area between the scaffolds and the border of the defect. This may impair the 
bone healing as the cells at the defect border are not in contact with the scaffold, 
thereby acquiring fewer cues to form bone, which may prolong the healing period. 
3D-printing can offer a solution. With 3D-printing, scaffolds designed and fabricated 
with precise dimensions and a defect-specific fit can be produced, enabling and 
possibly stimulating bone regeneration.
3D-printing
Techniques that create objects in a layer-by-layer fashion can all be described by the 
term ‘3D-printing’. Charles W. Hull described the first 3D-printing technique in 1984 
when he invented stereolithography (SLA) [33]. In this technique, solved monomers are 
photo-polymerized to fabricate a layer. Several 3D-printing techniques are used in tissue 
engineering, such as SLA, selective laser sintering (SLS), and extrusion-based printing. 
The properties of the material used and its application dictates which ‘printing’ technique 
can best be used. In SLS, a laser is used to sinter particles in a powder bed. This technique 
is often used in bone tissue engineering since structures with high porosity can be 
formed. Materials often printed using the SLS technology are HA, polycaprolactone (PCL), 
and poly (l-lactic acid) (PLLA). This technique is limited by its smallest attainable feature, 
which depends on the diameter of the laser and the size of the particles in the powder 
bed. Another downside is the impossibility to incorporate bioactive components, as 
the laser denatures these bioactive components. More and more research is done on 
extrusion-based printing, where materials are extruded from a nozzle. This technique 
allows for the fabrication of 3D scaffolds enhanced with biological components and/
or cells because it can be carried out at room temperature, thereby facilitating the 
opportunity to incorporate biological components and/or cells [34,35]. This technique 
is also compatible with the fabrication of CaP containing scaffolds. It is often based 
on the combination of CaP particles with a polymer, for instance, the combination of 
HA particles combined with polylactic-co-glycolic acid (PLGA) [36]. 3D-printing of CaP 
containing scaffolds for drug and growth factor delivery is a challenge. By using polymers 
like PLGA and PCL, often organic solvents, such as chloroform or dichloromethane are 
needed. However, these can denature the incorporated biological components. A 
solution can be found in the use of natural binders such as collagen and carrageenan. 
Collagen is an abundant part of the extracellular matrix, which makes it an interesting 
component for scaffolds. Carrageenan is derived from red seaweed, which makes it 
abundantly available and cheap. Furthermore, it resembles the glycosaminoglycans in 
the extracellular matrix [37].
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Most 3D-printed constructs with incorporated biological components designed for 
bone tissue engineering use BMP-2 [38,39] because, BMP-2 is an FDA approved (for 
anterior lumbar interbody fusion, acute open tibial fractures, and sinus and alveolar 
ridge augmentation [40] ) osteogenic agent, which promotes bone formation. 
Unfortunately, when applied in high concentrations it can also have negative side 
effects such as ectopic bone formation and inflammatory complications [41]. VitD3 
is another biological component often used in bone tissue engineering as it can 
promote the osteogenic differentiation of stem cells by upregulation of alkaline 
phosphatase (ALP) thus enhancing mineralization [19,20,42]. VitD3 can also influence 
osteoclastogenesis by inducing RANKL [43]. In this way, scaffolds that release vitD3 
may promote osteogenesis while also stimulating remodeling of the formed bone.
Previous research in our group showed that a slow-release system of precipitated CaP 
with incorporated BMP-2 promotes bone formation and induces ectopic ossification 
in rats [44,45]. To achieve a better fit in the bone defects in patients we see as a next 
stage the development of a method to 3D-print a similar system, where biological 
components are released to enhance the bone formation.
Aim and Outline of this thesis
The main aim of this thesis was to develop a 3D-printing method for calcium 
phosphate combined with biological components that 1) are capable of being 
released from the scaffold, and 2) retain their biological activity. This thesis is 
subdivided into four chapters.
To optimize 3D-printed scaffolds it is essential to know in which time frame biological 
components should be released from these scaffolds. In chapter 2, we investigated 
which release kinetic of vitD3 is more optimal for osteogenic differentiation of 
adipose stem cells in vitro. Based on previous research in our group, we hypothesized 
that a short incubation of 30 minutes would be more optimal for the osteogenic 
differentiation of adipose stem cells.
Bone tissue engineering constructs are placed in a bony environment. As there 
are different skeletal sites, the question arises if different bony-surroundings are 
differentially affected by such constructs. In chapter 3, we compared cells derived 
from human alveolar bone with cells derived from human long bone when studying 
their osteogenic and osteoclastogenic potential. We hypothesized that due to the 
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In chapter 4, we developed a method in which we can 3D-print precipitated calcium 
phosphate combined with natural binder κ-carrageenan. We investigate whether the 
incorporation of a biological component is possible and whether it is released from 
the printed constructs.
In chapter 5, we assessed the clinical relevance of 3D-printed constructs consisting of 
calcium phosphate paste and κ-carrageenan, enhanced with biological component 
vitD3. The printability, cytotoxicity, and apparent stiffness of the material were assessed. 
The effects of constructs with and without vitD3 on a human osteosarcoma cell line 
was also assessed.
Finally, the overall findings of this thesis are discussed in chapter 6 and summarized 
in chapter 7.
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Incorporation of 1,25(OH)2 vitamin D3 (vitD3) into tissue-engineered scaffolds could aid 
the healing of critical-sized bone defects. We hypothesize that shorter applications of 
vitD3 lead to more osteogenic differentiation of mesenchymal stem cells (MSCs) than a 
sustained application. To test this, release from a scaffold was mimicked by exposing 
MSCs to exactly controlled vitD3 regimens. Human adipose stem cells (hASCs) were 
seeded onto calcium phosphate particles, cultured for 20 days, and treated with 124 
ng vitD3, either provided during 30 min before seeding ([200 nM]), during the first two 
days ([100 nM]), or during 20 days ([10 nM]). Alternatively, hASCs were treated for two 
days with 6.2 ng vitD3 ([10 nM]). hASCs attached to the calcium phosphate particles 
and were viable (~75%). Cell number was not affected by the various vitD3 applications. 
VitD3 (124 ng) applied over 20 days increased cellular alkaline phosphatase activity at 
Days 7 and 20, reduced expression of the early osteogenic marker RUNX2 at Day 20, 
and strongly upregulated expression of the vitD3 inactivating enzyme CYP24. VitD3 
(124 ng) also reduced RUNX2 and increased CYP24 applied at [100 nM] for two days, 
but not at [200 nM] for 30 min. These results show that the 20-day application of vitD3 
has more effect on hASCs than the same total amount applied in a shorter time span.
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Introduction
Bone defects can occur as a consequence of birth defects, injury, cancer, or 
inflammation. Despite the good intrinsic healing capacity of bone, the reconstruction 
of critical size defects remains challenging. Currently, the “golden standard” for 
critical size bone defects is the use of autologous bone grafts [1]. These grafts are 
taken from the patient, often from the iliac crest, or in the case of orofacial defects 
from the symphysis of the chin or ascending ramus. Autologous bone is generally 
still considered the “gold standard” since it provides both an osteogenic and 
osteoconductive environment, due to the presence of live cells and the cocktail of 
growth factors present in the matrix [2]. However, this method suffers from two major 
drawbacks: donor site morbidity and lack of available tissue [3]. These drawbacks could 
be overcome by alternative approaches for bone reconstruction, such as methods 
employing principles of bone tissue engineering.
To regenerate bone, bone tissue engineering combines the use of biomaterials, e.g., 
polymer-based or calcium phosphate-based materials, cells, and physical, mechanical, 
and/or chemical stimuli [4], such as bone morphogenetic protein-2 (BMP-2) and 
vascular endothelial growth factor (VEGF) [5,6]. Another biological component used 
as a chemical stimulus in bone regeneration is 1,25(OH)2 vitamin D3 (vitD3), which 
promotes osteogenic differentiation of bone marrow-derived mesenchymal stem 
cells (BMSCs) and hASCs by upregulation of alkaline phosphatase (ALP) and enhancing 
mineralization [7–9].
For the delivery of biological components, for example, BMP-2 and vitD3, multiple 
delivery methods can be considered. Here, we focus on the three main delivery 
methods. First, an injection of bioactive factors into a carrier or injured site, or 
adsorption to a surface. This leads to a burst release where the biological component 
is depleted after a couple of days, as has been described for BMP-2 [10]. Supra-
physiological concentrations are often used in this case, which may lead to negative 
effects such as a growth-inhibition when vitD3 is used [11,12] or ectopic bone formation 
for BMP-2 [13]. Furthermore, in the case of expensive biological components such 
as BMP-2, this method can become costly. As a second method of release, avoiding 
supra-physiological concentrations, biomaterials can be used as release vehicles 
allowing a more sustained release [14–16]. A drawback of longer stimulation with 
biological components is that it can lead to the formation of inhibitors. For example, 
BMP-2 induces the expression of its antagonist noggin [17,18] and vitD3 induces the 
expression of Cytochrome P450 family 24 subfamily A member 1 (CYP24a1), an enzyme 
that inactivates vitD3 [19,20]. In addition, in natural bone development or healing, 
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cytokines, growth factors, or extracellular matrix components are usually transiently 
expressed [21,22]. Sustained expression of these factors hinders the progression of 
healing or development [23]. The third method is a short stimulation of stem cells 
with a bioactive factor (30 min or less) of cells, after which the biological component 
is washed away [24]. Mokhtari-Jafari et al. showed that such a short stimulation with 
vitD3 can lead to the differentiation of adipose stem cells into the osteogenic lineage 
[25]. Short incubation (15 or 30 min) with growth factors or other bioactive compounds 
suffices to induce long-lasting (weeks) effects on hASCs in cell culture [23,24]. In some 
cases, these effects even become more pronounced over time. To give an example, 
short incubation of BMP-2 triggers expression of the late marker osteocalcin in hASCs 
after 21 days of culture, but not at earlier time points [23]. Short stimulation can be 
used in a one-step surgery where the cells are harvested, stimulated shortly, and 
combined with a biomaterial serving as a scaffold, which can then be implanted, in 
one procedure. In this way, no exogenous ligands are placed into the body, avoiding 
possible side effects.
To shed light on the ongoing discussion whether short, burst or sustained release is 
the best method for the application of biological factors for bone tissue engineering, 
we designed an experiment where the in vivo situation was mimicked in a cell culture 
environment of hASCs seeded on BCP particles, allowing precise manipulation of 
doses and timing of application of a biologically active factor. We used vitD3, since 
we successfully used this factor to stimulate osteogenic differentiation of hASCs in 
conventional 2D cultures. Our aim was to investigate which application of vitD3, i.e., 
mimicking short exposure of cells ([200 nM] for 30 min), burst release from scaffolds 
([100 nM] for two days), or sustained release from scaffolds ([10 nM] for 20 days), leads 
to optimal osteogenic differentiation of hASCs (Figure 1). We hypothesized that shorter 
applications of vitD3 are more beneficial for osteogenic differentiation than a sustained 
application because longer applications may lead to the formation of inhibitors.
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Figure 1. Schematic representation of the different vitamin D3 applications. A total of 124 ng of vitD3 was 
added for either 30 min before seeding at a concentration of 200 nM (Short), for two days at a concentra-
tion of 100 nM (Burst high) to mimic a burst release, or for 20 days with a concentration of 10 nM (Sustained) 
to mimic a sustained release. Alternatively, cells were exposed to 10 nM vitD3 for two days (Burst low).
Materials and Methods
The release of vitD3 from scaffolds was mimicked by exposing the hASCs seeded on 
a 3D biomaterial to controlled vitD3 applications, and the viability, proliferation, and 
differentiation were measured.
Calcium Phosphate Particles
Clinically relevant, biphasic calcium phosphate (BCP, Straumann® BoneCeramic 60/40, 
Institut Straumann AG, Basel, Switzerland) particles with a particle size of 500–1000 
µm and a porosity of 90% were used to mimic calcium phosphate-containing scaffolds 
in vitro.
Isolation of hASCs
For the isolation of hASCs, subcutaneous adipose tissue from the abdominal wall 
was harvested from donors who underwent plastic surgery at the Tergooi Hospital 
Hilversum, the Netherlands. The study was conducted in accordance with the 
Declaration of Helsinki and the protocol was approved by the Ethical Review Board 
of the VU Medical Center, Amsterdam, the Netherlands (number 2016/105). Informed 
consent was obtained from all donors. Four of the donors were female and between 
33 and 56 years of age. Information on the fifth donor is unavailable.
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To isolate hASCS, adipose tissue was cut into pieces and digested enzymatically with 
0.1% collagenase A (Roche Diagnostics GmbH, Mannheim, Germany) which was 
added to phosphate-buffered saline (PBS; Thermo Fisher Scientific, Waltham, MA, 
USA) containing 1% bovine serum albumin (Roche Diagnostics GmbH) under stirring 
conditions for 45 min at 37 °C. This was followed by a Ficoll® density-centrifugation 
step (Lymphoprep; 1000× g, 20 min, – = 1.077 g/mL Ficoll®, osmolarity 280 ± 15 mOsm; 
Axis-Shield, Oslo, Norway) and the cell-containing interface was harvested and 
resuspended in Dulbecco’s modified Eagle’s medium (Life Technologies Europe BV, 
Bleiswijk, the Netherlands). hASCS were counted and stored in liquid nitrogen [24]. All 
experiments were conducted using the same five donors, but sometimes data from 
only four donors were available.
Platelet Lysate
Bloodbank Sanquin (Sanquin, Amsterdam, the Netherlands) provided pooled platelet 
products from multiple donors, which contained approximately 1 × 109 platelets per mL 
PAS-E/plasma (ratio 65:35) [47]. Platelets were lysed by a temperature shock at –80 °C to 
obtain platelet lysate (PL). Before use, PL was thawed and centrifuged at 600× g for 10 
min to remove the remaining platelet fragments. Finally, the supernatant was added to 
the medium at 5% (v/v) for the culturing of cells and 2% (v/v) for the experiments [48]. 
PL was used as a human cell culture supplement rather than bovine serum.
Culture and Treatment of hASCs
hASCs (1 × 105) from five independent donors were seeded, separately, on top of 
20 ± 1 mg BCP particles in 2 mL Eppendorf tubes. Before seeding, the BCP particles 
were soaked in 500 µL of Minimum Essential Medium ALPHA (α-MEM; Thermo Fisher 
Scientific) complemented with 1% Antibiotic Antimycotic Solution 100´ (Sigma, St 
Louis, MO, USA), 10 IU/mL heparin (Leo Pharma, Amsterdam, the Netherlands), 2% 
PL, and 50 µM ascorbic acid-2-phosphate (vitamin C; Sigma) for 30 min. For the short 
stimulation, the hASCs were treated with 124 ng of vitD3 for 30 min ([200 nM]), before 
seeding. Then, cells (all treatments) were allowed to attach to the BCP particles for 1 
h at 37 °C and transferred to 12 well plates with transwell inserts (pore size 3.0 µm; 
Greiner Bio-one, Alphen aan de Rijn, the Netherlands) with 0.5 mL of medium in the 
insert and 1 mL of medium in the well. For Burst and Sustained-release this medium 
was supplemented with the total amount of 124 ng of vitD3 (Sigma, stock: 30 µM 
in 100% ethanol, stored at -80 °C, in the absence of light) per well. Control cultures 
contained the same concentration of alcohol as in the sustained condition (3.35 µL 
100% alcohol per 10 mL of medium). The vitD3 treatment was provided either over 
the first two days (Burst-release high: [100 nM]) or over the total culture period of 20 
days (sustained-release: [10 nM]). In the condition “Burst-release low” (Burst low), the 
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hASCs were treated for two days after seeding with 6.2 ng vitD3 ([10 nM]) per day. A 
schematic representation of the applications is depicted in Figure 1. The medium of 
all conditions was refreshed daily.
Attachment and Viability
Attachment and viability were assessed using fluorescent microscopy. After two days, 
inserts were emptied, by cutting the membrane of the insert, in a clean 12-well plate. 
The medium was removed and the BCP particles with cells were washed once with 
PBS and incubated for 10 min with 5´ live/dead staining (Abcam, Cambridge, UK) in 
PBS. The dye was removed and 100 µL of PBS was added to the samples. The staining 
was analyzed with a fluorescence microscope (Leica Microsystems, Wetzlar, Germany) 
with a Nikon camera (Nikon, Tokyo, Japan). Brightness and contrast were adapted to 
enhance the visibility of the cells with Adobe Photoshop® 19.1.1 (Adobe Systems, San 
Jose, CA, USA). The number of live (green) and dead (red) cells were manually counted, 
but due to the difficulty of discerning individual cells, only qualitative assessments 
were made.
Metabolic Activity
The metabolic activity of hASCs was measured with AlamarBlue™ Cell viability reagent 
(Invitrogen, Carlsbad, CA, USA). Metabolic activity was measured on Days 2, 7, and 
20. Inserts with BCP particles were placed in a new set of wells and incubated for 4 
h at 37 °C with medium containing 10% AlamarBlue reagent (500 µL in the well and 
500 µL in the insert). After incubation, the medium in the insert was mixed with the 
medium in the well. From each sample, 100 µL (in duplicate) were transferred to a 
black 96-well plate and fluorescence was measured at 530–560 nm with Synergy HT® 
spectrophotometer (BioTek Instruments, Winooski, VT, USA). Medium without cells 
and with 10% AlamarBlue reagent was autoclaved to fully reduce the AlamarBlue 
reagent and used as a positive control. Samples are presented as a percentage of the 
positive control.
Alkaline Phosphatase (ALP)
hASCs were cultured on BCP particles for 7 and 20 days with the different vitD3 
applications or without vitD3. Cells were washed with PBS and lysed with 300 µL Milli-Q 
water and frozen at –20 °C for storage. After three freeze-thaw cycles, samples were 
collected by scraping. ALP was measured according to the method described by Lowry 
[49] using 4-nitrophenyl phosphate disodium salt at pH 10.3 as a substrate for ALP. 
Absorbance was measured at 405 nm with the Synergy HT® spectrophotometer. To 
correct for cell number, protein levels were measured using a bicinchoninic acid (BCA) 
Protein Assay Kit according to the manufacturers’ instructions (Pierce, Rockford, IL, 
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USA) and absorbance was read at 540 nm with Synergy HT® spectrophotometer. ALP 
was expressed as nmol/µg protein.
Quantitative Polymerase CHAIN reaction (qPCR)
After 7 and 20 days of culture, the inserts with the BCP particles were transferred 
to a clean 12-well plate. Total RNA was isolated with TRIzol® reagent (Invitrogen) 
following the manufacturer’s protocol. The concentration and 260/280 ratio of RNA 
were measured using a Synergy HT® spectrophotometer and 750 ng RNA was reverse-
transcribed to cDNA using RevertAid™ First Strand cDNA Synthesis Kit 1612 (Fermentas, 
St. Leon-Rot, Germany) according to the manufacturer’s protocol. For the qPCR 
reaction, cDNA was diluted 5´ and 1 µL was used, together with 3 µL PCR-H2O, 0.5 µL 
(20 µM) forward primer, 0.5 µL (20 µM) reverse primer, and 5 µL LightCycler® 480 SYBR 
Green I Mastermix (Roche Diagnostics). All measurements with a Ct value higher than 
36 were considered unreliable and discarded. The values of all genes were normalized 
to hypoxanthine phosphoribosyltransferase (HPRT) following the comparative cycle 
threshold (Ct) method and presented as the mean relative fold expression (2
−ΔCt). All 
primer sequences are listed in Table 1.
Table 1. Primer sequences.
Gene (Human) Forward Sequence Reverse Sequence
KI67 5’ CGAGACGCCTGGTTACTATCAA 3’ 5’ GGATACGGATGTCACATTCAATACC 3’
RUNX2 5’ CCAGAAGGCACAGACAGAAGCT 3' 5' AGGAATGCGCCCTAAATCACT 3’
COL1 5’ GCATGGGCAGAGGTATAATG 3’ 5’ GGTCCTTTGGGTCCTACAA 3’
BAX 5’ TGTCGCCCTTTTCTACTTTGC 3’ 5’ CTGATCAGTTCCGGCACCTT 3’
BCL-2 5’ AGAGCCTTGGATCCAGGAGAA 3’ 5’ GCTGCATTGTTCCCATAGAGTTC 3’
VDR 5’ GACACAGCCTGGAGCTGAT 3’ 5’ CAGGTCGGCTAGCTTCTGGA 3’
CYP24a1 5’ CAAACCGTGGAAGGCCTATC 3’ 5’ AGTCTTCCCCTTCCAGGATCA 3’
HPRT 5’ GCTGACCTGCTGGATTACAT 3’ 5’ CTTGCGACCTTGACCATCT 3’
OPN 5’ TTCCAAGTAAGTCCAACGAAAG 3’ 5’ GTGACCAGTTCATCAGATTCAT 3’
PPAR- γ 5’ CGACCAGCTGAATCCAGAGT 3’ 5’ GATGCGGATGGCCACCTCTT 3’
Statistical Analysis
Data were obtained from cultures of five independent donors (n = 5), performed 
in duplicate, and are presented as mean ± standard deviation (SD). Since the n was 
small, and the data are not normally distributed, the data were transformed with a 
log transformation. A paired t-test was conducted to test for statistical differences 
in gene expression levels between control and vitD3 applications per time point 
and treatment, for results depicted as single point graphs. Statistical comparisons 
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of the treatment groups (short, burst high, burst low, and sustained) in Alamar blue, 
protein content, ALP activity, and average gene expression levels were performed 
using repeated-measures ANOVA with Tukey’s post hoc test. P values of <0.05 were 
considered significantly different. Analyses were performed using GraphPad Prism 5.0 
(GraphPad Software, San Diego, CA, USA).
Results
hASCs Attached to BCP Particles and Survived, in the Presence and Absence of 
Vitamin D3
Before identifying the optimal vitD3 application, it needs to be established whether 
the hASCs are attached to the BCP particles. In Figure 2, representative micrographs 
for samples without vitD3 (Figure 2A, B) and with vitD3 (Figure 2C, D) are shown. The 
micrographs with vitD3 are from samples with the short application (200 nM: 30 min) 
of vitD3. These micrographs are representative for all vitD3 -treated samples. By manual 
counting of green and red cells, it was determined that a comparable number of hASCs 
had attached to the BCP particles at Day 2, regardless of vitD3 treatment. In all vitD3 
treated groups, as well as in the control group, the percentage of viable (green) cells 
was approximately 75%. No exact quantification is given per group, as this would 
misrepresent the reliability with which these numbers can be established, since it 
is extremely difficult to reliably visualize and discern individual cells in 3D seeded 
particles (Figure 2A–D).
Apoptosis induced by vitD3 was measured by gene expression of pro-apoptotic protein 
B-cell lymphoma protein 2 associated X (BAX) and its inhibitor B-cell lymphoma 2 
(BCL-2) (Figure 2E, F). The balance between BCL-2 and BAX protein expression strongly 
affects apoptosis in bone cells, whereby an excess of BCL-2 protects against apoptosis. 
In the current paper, BAX gene expression is therefore considered a pro-apoptotic 
marker, whereas enhanced BCL-2 gene expression is seen as a marker correlated 
with inhibition of apoptosis. At Day 7, Sustained application significantly increased 
the relative expression of BAX compared to the control and at Day 20. Burst high 
application of vitD3 significantly increased the expression of BAX at Day 20 compared 
to the control (Figure 2E). All other applications did not affect the gene expression of 
this pro-apoptotic factor. Average BAX expression did not significantly differ between 
vitD3-treated groups (Figure 2F). None of the vitD3 treatments had an effect on the 
expression of BCL-2 (Figure 2G). In general, the expression of BCL-2 appeared to be 
upregulated at later time points compared to earlier time points within the same vitD3 
treatment group, but this was not statistically tested (Figure 2G).
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Figure 2. Effect of vitamin D3 on the viability of hASCs on BCP particles. Fluorescence microscopy of 
live/dead staining shows the attachment and viability of hASCs on Day 2 after seeding. Living cells are 
stained green, while the red-stained cells are dead/dying. (A, B) Sample without vitD3 treatment, where 
(B) is a higher magnification of the same sample as (A). (C, D) A representative sample with vitD3 treatment 
(highest concentration, i.e., [200 nM]) is depicted. Both (C, D) were made in the same sample. (E) Gene 
expression of pro-apoptotic marker BAX measured at Days 7 and 20. Gene expression in controls (left) 
and vitD3-treated cultures (right) of the same donor are connected by a line. (F) Relative expression of BAX 
at Days 7 and 20. Data represent mean + SD of four or five independent donors. (G) Gene expression of 
anti-apoptotic marker BCL-2 measured at Days 7 and 20. Gene expression in controls (left) and vitD3-treated 
cultures (right) of the same donor are connected by a line. * Significant effect (p < 0.05) of vitD3 compared 
to the control at one-time point. ** p < 0.01. All gene expression levels were normalized to HPRT.
Vitamin D3 Did not Affect Proliferation of hASCS on BCP Particles
Having established that hASCs indeed attached to BCP particles and were viable in the 
early stage (Figure 2), we next assessed the effect of vitD3 on hASC proliferation. Alamar 
blue assay, gene expression of Ki67, and total protein levels were used as measures of 
cell number. Over time, between Days 2 and 20 the percentage of conversed Alamar 
blue, used as an indirect measure of cell number, increased on average 4.7-fold in 
all groups (Figure 3A). Compared to the control, VitD3 did not significantly affect the 
percentage of conversed Alamar blue for any mode of application, at any time point 
tested. The effect of the different vitD3-treatment kinetics on cell proliferation was 
also assessed by quantification of gene expression of the cell proliferation marker Ki67, 
which was not affected by vitD3 treatment (Figure 3B). For confirmation of cell number, 
total protein per condition was analyzed. In line with earlier results, total protein was 
comparable between the groups treated with and without vitD3 at Days 7 and 20 
(Figure 3C). Between Days 7 and 20, total protein seemed to increase similarly for all 
groups, but this was not statistically tested.
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Figure 3. Effect of vitamin D3 on proliferation and protein content of hASCs. hASCs were subjected to 
the various vitD3 treatment modalities and Alamar blue was measured at Days 2, 7, and 20; the gene ex-
pression of Ki67 was measured at Days 7 and 20, and total protein content was measured at Days 7 and 
20. (A) VitD3 treatment did not affect Alamar blue measurement between any of the groups, at any time 
point measured. (B) Gene expression of proliferation marker Ki67 did not significantly differ between 
vitD3-treated and control groups. Gene expression in controls (left) and vitD3-treated cultures (right) of 
the same donor are connected by a line. (C) Total protein content was similar between all vitD3-treated 
groups on Day 7, as well as on Day 20. Data represent four or five independent donors (mean + SD). Gene 
expression data were normalized to HPRT.
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Regime Mimicking Sustained Release of Vitamin D3 Affects ALP and RUNX2
The activity of ALP is an indication of early differentiation of the hASCs. ALP activity 
was measured on Days 7 and 20 and was divided by total protein (µg) levels to correct 
for approximate cell number. Sustained application of vitD3 significantly increased 
cellular ALP (Figure 4A). At Day 7, Sustained application increased the activity of 
ALP on average by 2.7-fold, compared to all the other conditions. On Day 20, this 
increase was 6.0-fold. Gene expression of runt-related transcription factor 2 (RUNX2), 
osteopontin (OPN), and collagen type 1a (COL1a) were measured as positive osteogenic 
differentiation markers. Adipogenic marker peroxisome proliferator-activated receptor 
gamma (PPAR-γ) was quantified as a negative marker for osteogenic differentiation. 
RUNX2 is an early differentiation marker which in general appeared to be upregulated 
at Day 20 compared to Day 7 within the same vitD3 treatment group, but this was not 
statistically tested. The Burst high application at Days 7 and 20 and the Sustained 
vitD3 application at Day 20 significantly downregulated the expression of RUNX2 
compared to their (paired) untreated controls (Figure 4B). When the rather variable 
RUNX2 expression levels were expressed as average, no significant difference in gene 
expression between the different vitD3-treated groups, and the control was found 
(Figure 4C). VitD3 did not significantly affect OPN, COL1a, or PPAR-γ expression at any 
concentration, at any time point (Figure S1).
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Figure 4. Effect of vitamin D3 on ALP activity and RUNX2 expression. (A) Cellular ALP, as a measure for early 
osteogenic differentiation, was measured on Days 7 and 20. Sustained-release significantly increased ALP 
activity compared to all other groups at both time points. (B) RUNX2 expression, in general, seemed to 
be higher at Day 20 compared to Day 7, although no statistical comparison was made. VitD3 seemed to 
reduce RUNX2 expression in general. This effect of vitD3 was significant for burst high at Days 7 and 2 and 
sustained application at Day 20. Gene expression in controls (left) and vitD3-treated cultures (right) of the 
same donor are connected by a line. (C) Average relative expression of RUNX2 at Days 7 and 20. Data rep-
resent four or five independent donors (mean + SD). All gene expression levels were normalized to HPRT. 
* Significant difference (p < 0.05) between control and vitD3 treatment at the same time point ** p < 0.01.
Sustained Application of Vitamin D3 Highly Upregulates CYP24a1 Expression
To analyze whether vitD3 stimulates a feedback loop causing insensitivity of the cells 
for vitD3 and inactivation of the vitD3 itself [26], the expression of vitamin D receptor 
(VDR) and CYP24a1 was measured. VDR was expressed at low levels on Day 7, regardless 
of the addition of vitD3. At Day 20, vitD3 seemed to have an overall stimulating, rather 
than inhibiting, effect on the expression of VDR. The stimulating effect of vitD3 on 
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VDR expression by hASCs was significant for Sustained and Burst low applications 
(Figure 5A). Average expression levels of VDR did not significantly differ between 
groups (Figure 5B). CYP24a1 converts the active form of vitD3 in Calcitroic acid, an 
inactive vitamin D metabolite [26]. All vitD3 applications, except for the condition 
“Short”, enhanced the expression of CYP24a1 compared to the control condition at Day 
7. At Day 20, Sustained and Burst low significantly increased CYP24a1 compared to the 
control (Figure 5C). At Days 7 and 20 Sustained vitD3 application strongly upregulated 
average expression levels of CYP24a1 compared to all other groups (Figure 5D).
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Figure 5. Gene expression of VDR and CYP24a1. (A) VDR expression. Data of controls (left) and vitD3 treated 
cells (right) from the same donor are connected with a line. (B) Average relative expression of VDR at Days 
7 and 20. Data represent four or five independent donors (mean + SD). (C) Burst high, Sustained, and Burst 
low application of vitD3 significantly increased CYP24a1 (note the 10-fold differences in axis scale). Data 
of controls (left) and vitD3 treated cells (right) from the same donor are connected with a line. (D) Average 
relative expression of CYP24a1 at Days 7 and 20. Data represent four or five independent donors (mean + 
SD). All gene expression data were normalized to HPRT. (A, C) * Significant difference (p < 0.05) between 
control and vitD3 treatment at the same time point; *** p < 0.001. (D) * Significant difference (p < 0.001) 
between Sustained vitD3 treatment and all other groups.
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Discussion
In this study, we evaluated which vitD3 application (Short, Burst, or Sustained) to 
hASCs seeded on BCP particles, leads to optimal osteogenic differentiation of hASCs 
in cell culture. We did this because we wished to mimic the effect of different release 
kinetics of vitD3 from biomaterials in vivo. Our results may help to design scaffolds 
with bioactive components for bone tissue engineering in a more targeted manner, 
and suggest that applying a daily dose of vitD3 in vitro (Sustained application), 
thereby mimicking a sustained release of vitD3 in vivo, stimulates ALP activity of 
hASCs, where other applications do not, even when the same total amount of vitD3 
(124 ng) was applied.
In this study, we mimicked short, burst, and sustained release from a scaffold. The 
same total amount of vitD3 was used for short, burst high, and Sustained applications 
(i.e., 124 ng), but delivered over different time spans, thereby leading to different 
concentrations. The concentration of 10 nM thus obtained for the Sustained 
application is a widely used concentration to induce osteogenic differentiation of 
MSCs[7,25,27]. Adding the same 124 ng vitD3 in two days (Burst high) or 30 min (Short) 
led to concentrations of 100 and 200 nM respectively. For Burst low, we applied the 
same concentration of vitD3 as the Sustained application (10 nM) but adhered to the 
same two-day timeframe as burst high, which means that the total amount of vitD3 
added to the ASCs over the total culture period was only 6.4 ng.
Our method of mimicking release from scaffolds has a limitation. The medium was 
refreshed every day to mimic a steady sustained release of bioactive components 
more accurately. This means the cells got a “shock” from the medium refreshment 
every day. This might have influenced the responses of the cells to vitD3 compared 
to more regular treatment regimens, where it is customary that cells are replenished 
two or three times a week. It could explain our relative lack of differentiation induced 
by vitD3, where we did not observe an obvious effect of vitD3 on ASC differentiation. 
Despite this downside, we were still able to discern clear effects of vitD3 on RUNX2, 
VDR, and CYP24 expression and ALP activity, and the cells used in the present study 
proliferated as normal (Figure 3). If our results are indeed somewhat “blunted” by 
the daily medium refreshments, it is to be expected that the observed differences of 
our in vitro investigation are more pronounced in vivo. In addition, the ASCs seemed 
to show an increased BCL-2 expression over time, while BAX expression remained 
level, indicating that the frequent medium refreshments did not induce apoptosis. 
Importantly, since all our groups were treated in exactly the same manner, we can 
readily compare the effects of our vitD3 applications between groups.
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One of the first prerequisites for successful tissue engineering approaches is the 
availability of sufficient numbers of cells. Cell number increases through proliferation 
or decreases through cell death. VitD3 (1–100 nM) shows an inverse linear relation with 
proliferation in human osteoblasts and C2C12 cells [28,29]. Whether vitD3 decreases 
proliferation in hASCs is unknown. A similar inhibition of proliferation of hASCs by 
vitD3 could have adverse effects on bone healing by limiting available cell numbers, 
unless perhaps the reduction in proliferation is explained by strong stimulation 
of differentiation. Unfortunately, the use of calcium-containing biomaterials did 
not permit us to use DNA as a measure for cell number, but we used the following 
surrogates for cell number: the Alamar blue assay (Figure 3A; which unfortunately 
also takes metabolic activity into account), histology (Figure 2A–D), and total protein 
(Figure 3C). In Figure 3C, it is clearly visible that the total protein content is highly 
similar between groups at Day 7. This is supported by the Alamar blue data from Day 2 
and 7, which show no differences. Based on these data, and the results from histology 
from Day 2, we can assume that the initial seeding of the particles was homogeneous. 
Our Alamar blue results, in combination with protein measurements, show that cell 
numbers varied very little between vitD3-treated conditions. Together, this indicates 
that the different vitD3 applications (Sustained (10 nM), Burst high (100 nM), Burst low 
(10 nM), or Short (200 nM)) neither reduced nor enhanced proliferation of ASCs (Figure 
3). This was confirmed by gene expression of Ki67, a marker for proliferation, which 
also showed no reduction.
Cell number can be affected by cell death, through necrosis or apoptosis. In large tissue 
engineering constructs, low oxygen tension in the center of the construct can lead to 
rapid loss of stem cells. Notably, vitD3 can cause apoptosis in mouse adipocytes (3T3-
L1) at a concentration of 77.4 nM ± 23.20 at Day 3 and 61.7 nM ± 20.5 at Day 6 [30] and 
breast cancer cells (MCF-7) at a concentration of 100 nM [31]. The results of the live-
dead staining at day 2 show that even the highest concentration of vitD3 (Short, 200 
nM) did not cause immediate cell death of hASCs. However, this does not guarantee 
that vitD3 does not induce cell death at later time points. We therefore, quantified 
gene expression of BAX and BCL-2 as a measure for apoptosis. Interestingly, the relative 
expression of BCL-2, an inhibitor of pro-apoptotic proteins, seemed to increase at Day 
20 compared to Day 7 (not tested), regardless of whether vitD3 was added, which 
suggests that inhibition of pro-apoptotic proteins increased over culture time. This 
general increase in BCL-2 has also been observed in human osteoblasts cultured on 
plastic with or without treatment of 10 nM vitD3 [32,33]. By Day 7, the gene expression 
of BAX, a pro-apoptotic molecule, had been upregulated in the condition mimicking 
sustained-release (10 nM per day for 20 days) and, by Day 20, the expression of BAX was 
upregulated by the condition mimicking burst release (100 nM per day for two days; 
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Figure 2E). The increase in BAX expression in these conditions may indicate initiation 
of apoptosis, but this also depends on the expression of BCL-2. Gene expression of 
BCL-2 was not significantly increased for any of the vitD3 treatments. Interestingly, 
total protein and Alamar blue did not show a decrease for Sustained and Burst high 
at any time point (Figure 3), suggesting that, if increased BAX expression was indeed 
translated into an increased balance between BAX and BCL-2 protein, then the impact 
on hASC apoptosis was minor. Our results together show that none of our vitD3 
applications seems harmful for hASCs.
Against expectations, expression of the early osteogenic marker RUNX2 appeared 
to be higher at Day 20 than at day 7, in both the presence and absence of vitD3. This 
trend was not statistically tested, but was striking, as the same pattern was observed 
for all treatment groups. As it has already been shown that calcium phosphate 
materials can induce the upregulation of RUNX2 [34] and that Ca2+ ions can play a 
role in the differentiation of stem cells/osteoblasts [35], we suspect that the apparent 
upregulation of RUNX2 over time is due to the BCP particles, which likely released ions 
in the medium, as they are known to do [35,36]. Burst high and Sustained application 
of vitD3 significantly reduced RUNX2 expression. This is in line with other studies [37,38] 
However, the average gene expression levels of RUNX2 did not significantly differ 
between treatment groups, suggesting that Burst high and Sustained had no superior 
effect on hASC differentiation with respect to RUNX2 expression.
Our results suggest that for the osteogenic differentiation of adipose stem cells 
cultured in 3D in vitro, continuous exposure to vitD3 or “Sustained release” might 
be preferable compared to shorter applications, but we are extremely careful with 
this conclusion, as it is based on ALP activity only. OPN expression was unaffected 
by vitD3 application, and, due to the use of BCP particles (containing calcium and 
phosphate), it was not possible to perform analyses such as alizarin red staining. 
However, at days 7 and 20, we found that the early osteogenic marker ALP had been 
significantly increased by the Sustained application. Mokhtari-Jafari et al. showed 
that a short (30 min) incubation of hASCs with vitD3 led to higher ALP expression 
than sustained incubation [25]. The contradictions between their findings and ours 
might be explained by a difference in concentration of the 30-min pre-incubation, 
as we used a 20´ higher concentration. Although the concentration they used for the 
sustained application is the same as in this study, the total amount of vitD3 sensed by 
our cells is higher, due to daily rather than twice-weekly refreshment of the medium. 
This indicates that for short incubation, the concentration of vitD3 may be important 
for the osteogenic differentiation of hASCS, while for sustained application the total 
amount applied may play a role as well, at least in vitro. This information could be 
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valuable for the development of scaffolds releasing bioactive components, assuming 
that our results translate to the in vivo situation.
A potential problem with the application of high amounts of active factors, or long 
durations of application of such factors, is that cells may respond less to further 
stimulation by those factors, through altered expression of receptors or inhibitors. 
VDR is the main receptor through which vitD3 regulates biological responses [36]. The 
expression of VDR in this study was quite stable, and, overall, the expression was not 
downregulated, indicating that the various vitD3 applications as used in the current 
study did not make the cells become less sensitive for vitD3. CYP24a1 converts the 
active vitD3 to an inactive form [39] and in our study, it was highly upregulated by 
Sustained application of vitD3. The rapid inactivation of vitD3 may have reduced the 
effect of Sustained vitD3 application on hASC differentiation, thereby explaining why 
the early osteogenic differentiation marker ALP was still upregulated at Day 20. On 
the other hand, ALP might still be upregulated at Day 20 because of the 3D culture 
system we used. ALP is an early marker when cells are cultured on plastic, but cultured 
in 3D the ALP expression increases slowly over time [40–42]. For future research, it is 
interesting to mimic a sustained release with even lower concentrations, since we 
speculate that this will decrease the inactivation of vitD3 by CYP24a1.
Sustained application stimulated ALP activity, where other applications of vitD3 did not, 
without inhibition of proliferation or reduction in cell number. This suggests that tissue 
engineering solutions in which an active compound such as vitD3 is released over a 
long period of time may be more beneficial for stimulating osteogenic differentiation 
than shorter durations of application. In line with these results, Faßbender et al. 
showed that sustained release of a low amount of BMP-2 had a similar positive effect 
on bone healing as higher BMP-2 amounts released with a burst [43]. On the other 
hand, a short application—if it works—can be clinically relevant as no exogenous 
ligands are placed in the body, thereby preventing potential adverse side effects. In 
the case of vitD3, this could be osteoclastogenesis. VitD3 can induce RANKL, which can 
induce the formation of osteoclasts as shown in a murine monocyte/macrophage 
cell line at doses as low as 10 nM, which is comparable to the concentration we used 
in the sustained application [44]. We do not expect these kinds of adverse effects of 
sustained-release from a biomaterial at lower concentrations, yet each patient reacts 
differently, and factors such as race and gender may affect the response to vitD3, 
therefore patient-specific treatment designs might be a good option to consider [45]. 
The clear donor to donor variability in the response to vitD3 treatment is visible in our 
data. This is most visible in the qPCR data (Figures 4 and 5) where in some cases the 
effect of vitD3 on gene expression is higher in two out of the five donors. The race of 
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our donors is unknown, which is unfortunate, as 25-hydroxyvitamin D3 serum levels 
and VDR expression vary between white and black people, possibly affecting the 
response to vitD3 [46]. Importantly, the donors that respond strongly to viD3 differ 
from gene to gene analysis, and there are no two individuals that can be designated 
as “high responders” vs. “low responders”. It is theoretically possible that hASCs from 
male donors react differently than those of females, but in our study at least four out 
of five of our donors are female.
In summary, although the effects of vitD3 on osteogenic differentiation were limited to 
ALP activity and RUNX2 expression, the results of this present study are still convincing 
enough to prompt us to reject our hypothesis that a short incubation with vitD3 would 
be more beneficial for osteogenic differentiation than other durations of applications. 
Adding vitD3 for a longer period did not lead to apoptosis, and induced the ALP 
expression at both Days 7 and 20. In addition, it affected gene expression of RUNX2, 
VDR, and CYP24a1. Short application did none of these things. Overall, a Sustained 
application seems to have more effect on hASCs compared to shorter applications, 
and therefore it would be wise to further investigate the effect of sustained release 
of vitamin D3 on proliferation and osteogenic differentiation of stem cells, taking into 








Figure S1. Relative gene expression of OPN, Col1a, and PPAR- γ (A) OPN expression was not affected by 
vitD3  at both day 7 and day 20. (B) Col1A expression was not affected by vitD3  at both day 7 and day 20. (C) 
PPAR-γ expression was upregulated at day 20 by sustained application of vitD3 but this is not significant. 
All genes were normalized to HPRT. The significant difference between control and treatment at each time 
point was measured using a paired t-test. Significance was considered when p<0.05.
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Osteoblasts derived from mouse skulls have increased osteoclastogenic potential 
compared to long bone osteoblasts when stimulated with 1,25(OH)2 vitamin D3 (vitD3). 
This indicates that bone cells from specific sites can react differently to biochemical 
signals, e.g., during inflammation or as emitted by bioactive bone tissue-engineering 
constructs. Given the high turn-over of alveolar bone, we hypothesized that human 
alveolar bone-derived osteoblasts have an increased osteogenic and osteoclastogenic 
potential compared to the osteoblasts derived from long bone. The osteogenic and 
osteoclastogenic capacity of alveolar bone cells and long bone cells were assessed in 
the presence and absence of osteotropic agent vitD3. Both cell types were studied in 
osteogenesis experiments, using an osteogenic medium, and in osteoclastogenesis 
experiments by co-culturing osteoblasts with peripheral blood mononuclear cells 
(PBMCs). Both osteogenic and osteoclastic markers were measured. At day 0, long 
bones seem to have a more late-osteoblastic/preosteocyte-like phenotype compared 
to the alveolar bone cells as shown by slower proliferation, the higher expression 
of the matrix molecule Osteopontin (OPN), and the osteocyte-enriched cytoskeletal 
component Actin alpha 1 (ACTA1). This phenotype was maintained during the 
osteogenesis assays, where long bone-derived cells still expressed more OPN and 
ACTA1. Under co-culture conditions with PBMCs, long bone cells also had a higher 
Tumor necrose factor-alfa (TNF-α) expression and induced the formation of osteoclasts 
more than alveolar bone cells. Correspondingly, the expression of osteoclast genes 
dendritic cell-specific transmembrane protein (DC-STAMP) and Receptor activator of 
nuclear factor kappa-B ligand (RankL) was higher in long bone co-cultures. Together, 
our results indicate that long bone-derived osteoblasts are more active in bone-
remodeling processes, especially in osteoclastogenesis, than alveolar bone-derived 
cells. This indicates that tissue-engineering solutions need to be specifically designed 
for the site of application, such as defects in long bones vs. the regeneration of alveolar 
bone after severe periodontitis.
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Introduction
One of the great challenges of periodontal treatment is the regeneration of the 
tooth-anchoring degraded alveolar bone. Surprisingly, little is known about both the 
osteogenic and osteoclastogenic capacity of the cells retrieved from this skeletal site. 
Bone tissue-engineering approaches using scaffolds are mostly based on research on 
long bones, whereas the restoration of alveolar bone between teeth after periodontal 
treatment is promoted by the cells derived from these unique alveolar bone structures. 
Ideally, the cells in the bone surrounding a tissue engineering construct are instructed 
by the signals emitted by the constructs to form bone, and also send cues to recruit 
stem cells, which can differentiate into cells that form bone. Cells from different skeletal 
sites may react differently to biological signals, e.g., as released by tissue-engineering 
constructs, such as vitD3 [1]. Furthermore, communication with other cell types might 
also be different. The reason why these cells may behave differently might lie in their 
origin, as alveolar bone originates from neural crest cells while long bone originates 
from the mesoderm [2].
An indication that cells from different skeletal sites may be different is shown by the 
in vitro comparison of orofacial and iliac crest human bone marrow stromal cells 
(hMSCs), where orofacial stromal cells were shown to have a higher proliferation and 
express higher levels of alkaline phosphatase (ALP), while the cells from the iliac crest 
responded more to osteogenic and adipogenic cues [3]. Another indication that there 
are differences between the cells from different skeletal sites is the cells’ responsiveness 
to biological components and drugs. In response to bone morphogenetic protein 2 
(BMP-2), orofacial hMSCs have a higher expression of osteogenic markers such as ALP 
and OPN than the cells from adult iliac crest [4]. Lastly, bisphosphonates are used 
to prevent the loss of bone density by reducing osteoclastic bone resorption and 
are therefore prescribed for patients with osteoporosis [5]. The fact that longer and 
higher treatment with bisphosphonates can lead to the necrosis of the jaw [6,7] and 
atypical femoral fractures [8,9] indicate that their effect on long bone differs from that 
on alveolar bone. These different responses indicate that for the most optimal effect, 
bone tissue-engineering constructs need to be developed site specifically.
For the remodeling of bone, both osteoblast and osteoclast are needed, where the 
osteoblasts form bone and osteoclasts resorb bone [10]. Several studies also show 
that osteoclasts differ between skeletal sites. Mouse osteoblasts from calvaria lead to 
a higher number of osteoclasts compared to osteoblast derived from long bones [1], 
and De Souza Faloni et al. show that marrows from mice, derived from the jaw and 
long bone, have different osteoclastogenic potential [11].
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This indicates that for optimal bone remodeling, the different effects of constructs 
on oseoclastogenesis also need to be considered and may also differ per skeletal site. 
Knowledge of local cells, such as the stem cells of the oral cavity [12], will ultimately 
lead to better healing and osseointegration of implants [13].
Biological components can be used to enhance bone tissue-engineering constructs. 
Moreover, vitD3 is such a biological component often used in bone tissue engineering 
as it can promote the osteogenic differentiation of hMSCs [14]. Moreover, vitD3 also 
affects the osteoclastogenic differentiation of osteoblasts in vitro by inducing the 
RankL expression [15]. We recently demonstrated that the way vitD3 is administered, 
mimicking release from tissue-engineering constructs, and affecting the osteogenic 
capacity of adipose tissue-derived mesenchymal stem cells [16].
In the present study, we compared the degree of differentiation of bone cells derived 
from human alveolar and long bones, their production of signaling molecules, and their 
ability to stimulate osteoclast formation in the presence or absence of the biological 
component vitD3. We hypothesize that alveolar bone cells have an increased osteogenic 
and osteoclastogenic potential compared to long bone cells, as alveolar bone cells seem 
to have a higher turnover, and therefore, we expect less differentiated cells.
Materials and Methods
Bone Cell Cultures
In this study, we used two types of cells: cells derived from alveolar bone and long 
bones, in this case, the tibia. Both cell types were obtained by the outgrowth of 
cells from pieces of bone. In short, bone fragments were transported in Dulbecco’s 
modified Eagle’s medium (DMEM, Gibco, Paisley, UK) supplemented with 2% antibiotic 
antimycotic solution 100× (Sigma, St. Louis, MO, USA) and then cut into small pieces, 
washed with PBS and were incubated for 2 h in 2 mg/mL collagenase II (Sigma, St. 
Louis, MO, USA) in DMEM at 37 –C in a shaking water bath. The bone fragments were 
washed with a medium containing 10% fetal calf serum (FCS) and transferred to 25 cm2 
flasks. Bone fragments were cultured in DMEM with 1% antibiotic antimycotic solution 
100× and 10% FCS. When the cells reached confluency, the cells were harvested using 
0.25% trypsin and 0.1% EDTA in PBS. For each cell type, we used cells from 5 different 
donors. Cells were not from the same donors and are from passage 2–4. The donors 
for the long bone cells were all female and were between 69-86 years of age. Of the 
alveolar bone cell donors, two were male and three were female with an age between 
37 and 60.
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Alveolar Bone Cells
Cells were derived from human interdental alveolar crest bone. Patients who were 
referred for multiple adjacent tooth extractions and immediate denture placement 
were asked to participate. Interdental alveolar crestal bone was regarded as surgical 
waste since this bony rim has to be smoothened before wound closure. Treatments 
took place at the Department of Oral and Maxillofacial Surgery at the hospital OLVG 
in Amsterdam, The Netherlands. Prior to the treatment, written informed consent was 
signed by the patienst, and the study protocol was approved by the research ethics 
committee of the OLVG (protocol-ID: WO17.194).
Long Bone Cells
Cells were derived from surgical waste from human bone from the knee, after surgery 
performed at the VU University Medical Center, Amsterdam, The Netherlands. This in 
agreement with The Ethical Review Board of the VU Medical Center, Amsterdam, The 
Netherlands, under protocol number 2016/105.
Osteogenesis Experiments
For the osteogenesis experiments, cells either derived from long bone or alveolar bone 
were seeded at 3 × 104 cells/well in a 48-well plate and cultured in a basic medium, one 
day before the start of the experiment (day−1). At day 0, the medium was refreshed and 
the cells were cultured in basic medium, osteogenic medium, or osteogenic medium 
supplemented with vitD3. The basic culture medium consisted of the D modification 
of Dulbecco’s modified Eagle’s medium (DMEM, Gibco BRL, Paisley, Scotland), 5% fetal 
clone I serum (FCI, HyClone, Logan, UT), 5% fetal clone III serum (FCIII, HyClone) and 1% 
Antibiotic Antimycotic Solution, 100× (Sigma, St. Louis, MO, USA). Osteogenic medium 
is a basic medium supplemented with 50 µM ascorbic acid-2-phosphate (Sigma, St. 
Louis, MO, USA) and 50 µM β-Glycerophosphate (Sigma). In some cultures, osteogenic 
medium was supplemented with 10 nM vitD3 (osteogenic + vitD3). The medium was 
refreshed twice a week for 3 weeks.
Alkaline Phosphatase (ALP) Activity
Cells were lysed with 200 µL of Milli-Q water at day 0, day 7, day 14, and day 21 and 
frozen at -20 –C. Samples were collected by scraping after 3 freeze-thaw cycles for 
ALP measurement. ALP was measured using 4-nitrophenyl phosphate disodium salt 
at pH 10.3 as a substrate for ALP, a method described by Lowry [34]. Absorbance was 
measured at 405 nm with Synergy HT® spectrophotometer. ALP levels were corrected 
for DNA content and expressed as µmol/ng. DNA was measured using a Cyquant 








Cells were cultured for 21 days to test for mineralization of the cells. All the samples 
were washed with deionized water and fixed with 4% formaldehyde for 10 min. After 
rinsing with deionized water, 300 µL of 2% Alizarin red S (Sigma-Aldrich) staining with 
a pH of 4.3 was added to each well. After a 15-min incubation, the cells were washed 
and air-dried.
Quantitative Polymerase Chain Reaction (qPCR)
At day 0, and after 14 days and 21 days of culture, the total RNA was isolated with 
TRIzol® reagent (Invitrogen) following the manufacturer’s protocol. The quality and 
concentration of the RNA were measured using a Synergy HT® spectrophotometer. 
Then, 750 ng RNA was reverse-transcribed to cDNA using the RevertAid™ First 
Strand cDNA Synthesis Kit 1612 (Fermentas, St. Leon-Rot, Germany) according to the 
manufacturer’s protocol. For the qPCR
reaction, cDNA was diluted 5× and 1 µL was used, together with 3 µL PCR-H2O, 0.5 µL 
(20 µM) forward primer, 0.5 µL (20 µM) reverse primer, and 5 µl LightCycler® 480 SYBR 
Green I Mastermix (Roche Diagnostics, Mannheim, Germany). All the measurements 
with a Ct value higher than 36 were considered unreliable and discarded. The values of 
all the genes were normalized to hypoxanthine phosphoribosyl transferase (HPRT) or 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) following the comparative cycle 
threshold (Ct) method and presented as the mean relative fold expression (2−∆Ct). All 
the primer sequences for osteogenesis experiments are listed in Table 1.
Table 1. Primer sequences osteogenesis.
Gene (Human) Forward Sequence Reverse Sequence
COL1 5’ GCATGGGCAGAGGTATAATG 3’ 5’ GGTCCTTTGGGTCCTACAA 3’
RUNX2 5’ CCAGAAGGCACAGACAGAAGCT 3’ 5’ AGGAATGCGCCCTAAATCACT 3’
OPN 5’ TTCCAAGTAAGTCCAACGAAAG 3’ 5’ GTGACCAGTTCATCAGATTCAT 3’
DMP-1 5’ TAGGCTAGCTGGTGGCTTCT 3’ 5’ AACTCGGAGCCGTCTCCAT 3’
ACTA1 5’ CTGGCA’CCACACCTTCTACA 3’ 5’ CACGCTCAGTGAGGATCTT 3’
IL-6 5’ ACAGCCACTCACCTCTTCA 3’ 5’ ACCAGGCAAGTCTCCTCAT 3’
COX2 5’ GCATTCTTTGCCCAGCACTT 3’ 5’ AGACCAGGCACCAGACCAAAGA 3’
CYR6 5’ TCCGAGGTGGAGTTGACGAGAA3’ 5’ TTCACAAGGCGGCACTCAGG 3’
HPRT 5’ GCTGACCTGCTGGATTACAT 3’ 5’ CTTGCGACCTTGACCATCT 3’
GAPDH 5’ TGGGTGTGAACCATGAGAAGTATG 3’ 5’ GGTGCAGGAGGCATTGCT 3’
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Osteoclastogenesis Experiments
To analyze the capacity of alveolar bone and long bone-derived cells to contribute to 
osteoclast formation, these cells were seeded at 1.5 × 104 cells/well in a 48-well plate 
and allowed to spread overnight (day −1). The next day (day 0), 0.5 × 106 peripheral 
blood mononuclear cells (PBMCs) were seeded on top. The PBMCs were isolated 
from the buffy coat (Sanquin, Amsterdam, The Netherlands) by a standard density 
gradient centrifugation with Ficoll-Paque [35]. Co-cultures of bone cells and PBMCs 
were cultured for up to 21 days in basic medium (same composition as the basic 
medium in the osteogenesis experiments) or the basic medium supplemented with 10 
nM vitD3. The medium was refreshed twice a week. As a control, the PBMCs on plastic, 
also without the supplementation of RankL and the macrophage colony-stimulating 
factor (M-CSF), were used.
ELISA
After 7 days of culture, the supernatant of the osteoclastogenesis plate was collected 
and the Enzyme Linked Immunosorbent Assays were performed with the DuoSet 
ELISA kits (R&D systems, Abington, United Kingdom) for the human TNF-α, and IL-1β, 
following the manufacturer’s protocol.
Osteoclast Quantification
After 21 days of culture, the cells were fixed with 4% formaldehyde for 10 min and 
stained with leukocyte acid phosphatase kit (Sigma) to identify the TRAcP activity. The 
nuclei were stained with diamidino-2phenylindole dihydrochloride (DAPI). The whole 
culture well was analyzed for the number of osteoclasts. Osteoclasts were considered 
as TRAcP+ multinucleated cells (MNCs) containing three or more nuclei. Two groups 
were counted, cells with 3–5 nuclei and cells with more than 5 nuclei.
qPCR
At day 0, and after 14 days and 21 days of culture, the total RNA was isolated with 
TRIzol® reagent (Invitrogen) following the manufacturer’s protocol. The quality and 
concentration of the RNA were measured using a Synergy HT® spectrophotometer. 
Then, 750 ng RNA was reverse-transcribed to cDNA using the RevertAid™ First 
Strand cDNA Synthesis Kit 1612(Fermentas, St. Leon-Rot, Germany) according to 
the manufacturer’s protocol. For the qPCR reaction, cDNA was diluted 5× and 1 µL 
was used, together with 3 µL PCR-H2O, 0.5 µl (20 µM) forward primer, 0.5 µL (20 µM) 
reverse primer, and 5 µL LightCycler® 480 SYBR Green I Mastermix (Roche Diagnostics, 
Mannheim, Germany). All the measurements with a Ct value higher than 36 were 
considered unreliable and discarded. The values of all the genes were normalized 
to HPRT or GAPDH following the comparative cycle threshold (Ct) method and 
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presented as the mean relative fold expression (2−∆Ct). All the primer sequences for 
osteoclastogenesis experiments are listed in Table 2.
Table 2. Primer sequences osteoclastogenesis.
Gene (Human) Forward Sequence Reverse Sequence
DC-STAMP 5’ ATTTTCTCAGTGAGCAAGCAGTTTC 3’ 5’ AGAATCATGGATAATATCTTGAGTTCCTT 3’
Tracp 5’ CACAATCTGCAGTACCTGCAAGGAT 3’ 5’ CCCATAGTGGAAGCGCAGATA 3’
IL-6 5’ ACAGCCACTCACCTCTTCA 3’ 5’ ACCAGGCAAGTCTCCTCAT 3’
RankL 5’CATCCCATCTGGTTCCCATAA 3’ 5’ GCCCAACCCCGATCATG 3’
OPG 5’ TGGAATAGATGTTACCCTGTGTG 3’ 5’ GCTGCTCGAAGGTGAGGTTA 3’
COX2 5’ GCATTCTTTGCCCAGCACTT 3’ 5’ AGACCAGGCACCAGACCAAAGA 3’
HPRT 5’ GCTGACCTGCTGGATTACAT 3’ 5’ CTTGCGACCTTGACCATCT 3’
GAPDH 5’ TGGGTGTGAACCATGAGAAGTATG 3’ 5’ GGTGCAGGAGGCATTGCT 3’
Statistics
Data were obtained from the cultures of 5 independent donors (n = 5) for each cell 
type. Data are presented as mean + standard deviation (SD). A t-test was conducted 
to test for the statistical differences between the alveolar bone cells and the long 
bone cells at day 0 (Figure 1). The differences between the groups in the number of 
osteoclasts are measured with a one-way ANOVA with a Tukey post hoc test. Statistical 
comparisons of the experiments with multiple
time points were done using a 2-way ANOVA with Bonferroni post-tests. With time 
and ‘cell type’ used as the dependent variables, the P values of < 0.05 were considered 
significantly different. The analyses were performed using GraphPad Prism 5.0 
(GraphPad Software, San Diego, CA, USA).
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Results
Alveolar Bone Cells and Long Bone Cells Differ in Basic Appearance, Prolifera-
tion, and Expression of Mature Bone Cell Markers
To identify the differences between the alveolar-derived bone cells and the long bone-
derived cells, it is first of all important to know the baseline characteristics of the cells 
derived from both skeletal sites. We tested the differences in appearance, proliferation, 
and bone markers. In Figure 1A, B, representative micrographs of the cells derived from 
bone harvested at both sites, cultured on tissue culture plastic on day 7, are shown. 
At confluence, alveolar bone cells (Figure 1A) had a fibroblastic appearance, while the 
appearance of long bone cells was more cuboidal (Figure 1B). The proliferation of the 
cells was measured with the total DNA content (Figure 1C). At both days 14 and 21, 
there was significantly more DNA in the alveolar bone samples, indicating the higher 
proliferation for the cells derived from the alveolar bone. At day 14, there was 2.9-
fold more DNA in the samples derived from alveolar bone cells compared to the long 
bone cells, and at day 21 there was 1.6-fold more DNA in the alveolar bone samples 
compared to the long bone samples. The gene expression of several bone markers 
(Figure 1D–H) was measured at day 0. The relative expression of extracellular matrix 
protein Collagen type I (Col1A) (Figure 1D) and the differentiation marker Runt-related 
transcription factor 2 (RUNX2) (Figure 1E) seemed higher in the cells derived from the 
long bones but this was not significant. In contrast, all the relatively late markers, OPN 
(Figure 1F), Dentine matrix protein 1 (DMP-1) (Figure 1G), and ACTA1 (Figure 1H) were 
significantly higher expressed in long bone cells than in alveolar bone cells.
3
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Figure 1. Basic differences between the cells from the alveolar bone and long bones. Light microscopy of 
(A) the alveolar bone cells and (B) the long bone cells at day 7. (C) DNA content, as a measure of the number 
of cells at a given time point, of both cells derived from alveolar bone and the long bone at day 0, day 7, 
day 14, and day 21. To gain insight into the osteogenic lineage of both cell types, the gene expression of 
osteogenic genes was assessed at day 0 (D–H) The relative expression of both (D) Col1a and (E) RUNX2 
was comparable in both the alveolar bone cells and the long bone cells. The relative expression of (F) 
OPN, (G) DMP-1, and (H) ACTA1 was significantly higher at day 0, in long the bone cells compared to the 
alveolar bone cells. Significance for DNA was measured using 2-way ANOVA with Bonferroni post-tests. 
For the relative gene expression, significance was measured using a t-test.
* p < 0.05, ** p < 0.01.
3
559887-L-bw-Kelder
Processed on: 6-5-2021 PDF page: 58
58
Chapter 3
Cells Derived from Long Bone Have a Higher Expression of Late Osteogenic 
Markers Compared to Alveolar Bone Cells
Having determined the basic differences between alveolar bone cells and long bone 
cells, we then assessed the osteogenic potential of both cell types. We tested this 
potential with an osteogenic medium and an osteogenic medium supplemented 
with vitD3. Cellular ALP activity levels (Figure 2A) were similar in alveolar bone and 
the long bones under all conditions. The differentiation marker RUNX2 was under 
basic circumstances, significantly higher expressed by the alveolar bone cells than by 
long bone cells at day 21. This difference was not present when vitD3 was added. VitD3 
upregulated the gene expression of RUNX2 of long bone cells (Supplementary Materials 
Figure S1A). The relative expression of Col1a was similar in all conditions (Figure 2C). OPN 
expression appeared higher in the long bone samples compared to the alveolar bone 
samples for all conditions, but was only significantly higher at day 14 in a basic condition 
and day 21 in the condition with vitD3. Over time, the expression of DMP-1 significantly 
increased in alveolar bone cell cultures in basic condition (Figure 2E). The osteogenic 
medium led to a significant increase in DMP-1 expression when comparing day 14 with 
day 21, in both alveolar bone cells and long bone-derived cells. The expression of DMP-1 
was upregulated by the supplementation of vitD3 in long bone cells, specifically at day 21 
(Supplementary Materials Figure S1B). At this time point, it was also significantly higher 
than the DMP-1 expression in alveolar bone cells. The ACTA1 expression was higher in 
the long bone cells than in the alveolar bone cells both in the basic and osteogenic 
conditions (Figure 2F). The addition of vitD3 seemed to lower the expression for both 
cell types at day 14. At day 21, the expression was significantly upregulated for both cell 
types and there was a significant difference between the alveolar bone cells and the 
long bone cells. The calcium deposits as a measure for mineralization were assessed 
using alizarin red staining. At day 21, there were no calcium deposits visible in both cell 
types (Supplementary Materials Figure S1C).
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Figure 2. The osteogenic potential of the alveolar bone cells and the long bone cells in the osteogenic 
medium and the osteogenic medium supplemented with vitD3. Graphs depict the relative expression in 
the basic, osteogenic, and osteogenic + vitD3 conditions of the cells derived from the alveolar bone and 
the long bone. Since the osteogenic differentiation is usually assessed at 14 and 21 days, the expression 
was measured at day 14 and day 21. (A) Cellular alkaline phosphatase (ALP) expression corrected for the 
DNA levels. (B) RUNX2 expression. (C) Col1a expression. (D) OPN expression. (E) DMP-1 expression. (F) 
ACTA1 expression. Significance was measured using 2-way ANOVA with Bonferroni post-tests. * p < 0.05.
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Communication Genes in Osteogenic Conditions of Alveolar Bone Cells and 
Long Bone Cells
After assessing the osteogenic potential for both cell types, we next wanted to 
determine if the alveolar bone cells and long bone cells differed in the expression of 
molecules that are associated with communication. The expression of Interleukin 6 (IL-6) 
(Figure 3A), Cyclo-oxygenase-2 (COX2) (Figure 3B), and Cysteine-rich angiogenic inducer 
61 (CYR61) (Figure 3C) were measured. IL-6 can be secreted by osteoblasts to stimulate 
the formation of osteoclasts, but IL-6 also stimulates the differentiation of osteoblasts. 
At day 0, the relative expression of IL-6 was significantly higher in long bone cells 
(Figure 3A). The osteogenic medium influenced the expression of IL-6 differently in the 
two cell types. In the alveolar bone cells, it seems to be inhibited while it induced the 
expression in long bone cells. The expression was significantly higher in the long bone 
cells compared to the alveolar-derived bone cells (Supplementary Materials Figure 
S2A). The supplementation of vitD3 induced the expression of IL-6 both in the cells 
derived from alveolar bone and long bone, but there was no difference in the gene 
expression between the cells (Supplementary Materials Figure S2A). COX2 is needed 
for normal fracture healing [17]. The relative expression of COX2 was 3.3-fold higher 
in the long bone cells at day 0. At day 14 and day 21, the expression levels were similar 
between long bone and alveolar bone cells. The osteogenic medium upregulated the 
COX2 expression, particularly in alveolar bone cells, leading to a 5-fold difference in 
the expression between the two cell types at day 21. Interestingly, supplementation 
with vitD3 induced the expression of COX2 in long bone cells, especially on day 21 
(Supplementary Materials Figure S2B). Besides being a matrix protein, CYR61 promotes 
osteogenic differentiation [18]. Long bone cells expressed more CYR61 than alveolar 
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Figure 3. Differences in the expression of mRNAs associated with communication in the osteogenic con-
ditions of the alveolar bone cells and the long bone cells. Graphs depict the relative expression in the 
basic, osteogenic, and osteogenic + vitD3 conditions of the cells derived from the alveolar bone and the 
long bone. Relative expression was measured at day 0, day 14, and day 21. (A) Relative expression of IL-6. 
(B) Relative expression of COX2. (C) Relative expression of CYR61. The significance of the relative gene 
expression was measured using a 2-way ANOVA with Bonferroni post-tests. * p < 0.05.
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Long Bone Cells Induce More Osteoclast Formation than Alveolar Bone Cells
Besides the osteogenic potential of both cell types, we also assessed the 
osteoclastogenic potential of the cell types. After 21 days of culture, the total 
number of osteoclasts was counted (Figure 4A). A distinction was made between the 
osteoclasts with 3–5 nuclei and 6+ nuclei, but only the total number of osteoclasts 
was shown since low numbers of larger osteoclasts were counted. On average, 19.2 ± 
20.4 large osteoclasts were found in long bone, 2.9 ± 4.3 in alveolar bone, and 0.8 ± 
0.5 in peripheral blood mononuclear cells (PBMCs) only (no bone) cultures. There were 
significantly more osteoclasts induced by long bone cells than by alveolar bone cells 
and PBMCs only, as a control condition. In the condition with vitD3, the same trend is 
visible although not significantly. Interestingly, similar numbers of osteoclasts were 
counted in alveolar bone-PBMC co-cultures as in the PBMCs alone control cultures. 
In this control condition, without bone-derived cells, this was 93.8 ± 51 and 100 ± 25 
osteoclasts, respectively, and in the condition supplemented with vitD3, it was 145.4 
± 114.8 and 104.3 ± 17.1 osteoclasts, respectively. In line with the increased osteoclast 
counts in long bone-PBMC co-cultures, the relative expression of osteoclast marker 
DC-STAMP was significantly higher in long bone at day 14 and day 21 (Figure 4B). At 
day 14, the average expression was 4.3-fold higher and 4.6-fold higher at day 21. In 
the condition with vitD3, the expression of DC-STAMP was higher in long bones, which 
was significant at day 14. The relative expression of Tartrate-resistant acid phosphatase 
(TRAcP) was significantly higher in the control condition in the long bone cells at day 
21 (Figure 4C). In the condition with vitD3, there were no differences.
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Figure 4. The osteoclastogenic potential of the alveolar bone cells and the long bone cells in the basic 
medium and the basic medium supplemented with vitD3. The osteoclastogenic potential of the co-cul-
tures with the PBMCs and long bone cells and the PBMCS and alveolar bone cells. Graphs depict the basic 
medium and the basic medium + vitD3. (A) The total number of osteoclasts induced by the Alveolar bone 
cells, long bone cells, and the PBMCs alone at 21 days. Differentiation was further assessed with qPCR 
for osteoclast-specific genes (B, C). (B) The relative expression of DC-STAMP. (C) Relative expression of 
TRAcP. Significance for the number of osteoclasts was measured using a one-way ANOVA with a Tukey 
post-hoc test and the significance of the relative gene expression was measured using 2-way ANOVA with 
Bonferroni post-tests. * p < 0.05.
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Expression of Pro-Osteoclastogenesis Proteins and mRNAs
To explain the higher numbers of osteoclasts formed during the co-culture with long 
bone cells, compared to the alveolar bone-derived cells, we then assessed TNF-α and 
Interleukin-1 beta (IL-1β) in the supernatant of the osteoclastogenesis experiments 
(Figure 5A). The concentrations were determined at day 7, the time point with the 
peak expression of TNF-α [19]. The concentration of TNF-α was significantly lower in 
the co-cultures with alveolar bone cells (24 pg/mL) than in the co-cultures with long 
bone cells (114 pg/mL) and PBMSc alone (102 pg/mL). The concentration seemed lower 
when vitD3 was added in all groups. The concentration of IL-1β was too low to detect 
in all conditions. The relative expression of IL-6 in the basic condition increased after 
day 0 for both cell types (Figure 5B). In the condition with vitD3, no differences were 
present. The expression of IL-6 in the osteoclastogenesis experiments was on average 
369-fold higher at day 14 and 395-fold higher at day 21 than the IL-6 expression in the 
osteogenesis experiments under basic culture conditions. The relative expression of 
RankL was higher in the long bone cells than in alveolar bone cells, significantly so at 
day 14 (Figure 5C). Although adding vitD3 caused a significantly higher expression of 
RankL in the long bones cultures at day 14 compared to the alveolar bone co-cultures, 
it decreased at day 21. Osteoprotegerin (OPG) is an important negative regulator of 
osteoclast differentiation. Under basic conditions, its expression decreased at day 14 
in long bone-PBMC co-cultures (Figure 5D). Supplementation with vitD3 did not lead 
to a difference between the long bone cells and alveolar bone cells. The ratio of RankL 
and OPG is generally used as an indication of osteoclast differentiation. At day 14, this 
ratio is significantly higher (19.6-fold) in the long bone cells than in alveolar bone cells 
(Figure 5E), concomitant with the increased osteoclastogenesis by long bones. VitD3 
lowers this ratio. In alveolar bone cells, the expression of COX2 was on average 9.2-
fold higher than in long bones at day 14 and 5.6-fold at day 21 (Figure 5F). At day 14, 
the supplementation of vitD3 led to the inhibition of COX2 expression and induced its 
expression in long bone cells (Supplementary Materials Figure S3).
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Figure 5. Differences in the proteins and the genes involved with osteoclastogenic differentiation in the 
alveolar bone cells and the long bone cultures. Graphs depict the basic medium and the basic medium + 
vitD3 (A) Concentration of TNF-α in media at day 7. (B) Relative expression of IL-6. (C) Relative expression 
of RankL. (D) Relative expression of osteoprotegerin (OPG). (E) The ratio RankL/OPG gives an indication for 
osteoclast activation. (F) Relative expression of COX2. Significance was measured using a 2-way ANOVA 
with Bonferroni post-tests. * p < 0.05.
3
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In this study, we compared the ability of bone cells derived from human alveolar and 
long bones to differentiate towards mature bone-forming osteoblasts, and their ability 
to stimulate osteoclast formation. These experiments were performed in the presence 
and absence of vitD3, since vitD3 could stimulate differentiation when incorporated 
in tissue-engineering constructs as we have recently proposed [16]. We found that 
under basic conditions without VitD3, long bone cells seemed to be more differentiated 
than alveolar bone cells, both at baseline and over time. Furthermore, long bone-
derived cells induced more osteoclasts than alveolar bone cells. Taken together, our 
results suggest that long bone-derived cells are more differentiated, more actively 
communicate with osteoclast precursors, and have a stronger osteoclastogenic 
potential than alveolar bone cells.
Although the cells derived from both skeletal locations were isolated using the same 
protocol, the cells differed in their basic appearance, proliferation, and expression of 
bone markers. The long bone cells in our study had a more cuboidal appearance at day 
7, while alveolar bone cells had a fibroblastic appearance. This indicates that long bone 
cells have a more osteoblastic appearance from the start, as osteoblasts are cuboidal-
shaped cells. In vivo, this cuboidal appearance is required for tightly connecting to 
neighboring cells, needed for the consort deposition of osteoid [20,21]. Alveolar bone-
derived cells proliferate faster than the cells derived from long bones, and this might 
have to do with the higher bone turnover in the jaw [22] and is also in line with a less 
differentiated state. Several late to very-late bone differentiation markers (OPN, DMP-1, 
and ACTA1) were higher expressed in long bone cells than in alveolar bone cells (Figure 
1), underscoring their more mature, differentiated phenotype. OPN is a protein used as 
a marker for osteogenic differentiation. DMP-1 is a bone mineralization marker and is 
expressed in early and mature osteocytes [23]. Furthermore, ACTA1 is highly expressed 
in osteocytes [24]. Taken together, our data suggest that long bone cells have a more 
late-osteoblastic/preosteocyte-like phenotype than alveolar bone-derived cells.
Besides the basic differences, we also compared the osteogenic differentiation of 
both cell types. Again, the cells derived from long bones showed a higher degree 
of differentiation, as OPN and ACTA1 expression was higher and vitD3 induced the 
expression of RUNX2 and DMP-1 more in long bone cells than in alveolar bone cells 
(Figure 2). This is in contrast with the stronger osteogenic potential described by 
Aghaloo et al. in mandibular MSCs compared to the MSCs from long bones [25]. This 
difference might lie in the cell source; they used cells derived from rats, we used cells 
from human donors.
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Rats continue to grow throughout their lifespan, whereas humans do not. Moreover, 
alveolar bone-derived cells might differ from the cells derived elsewhere from 
the mandibula. Differences in the effect of vitD3 on osteoblasts were also found in 
murine osteoblasts, where vitD3 had no effect on the osteoblast derived from long 
bones while inhibiting mineralization by calvarial osteoblasts [26]. In this study, both 
the cells derived from alveolar bone and long bone did not mineralize at day 21. 
Ruppeka-Rupeika et al. showed that alveolar bone-derived cells are capable of forming 
mineralizing nodules at day 21 [27]. One of the differences between the study by 
Ruppeka-Rupeika and our study is the serum that was used to culture the cells. They 
only used FC1, while for the current comparison we used a combination of FC1 and 
FC3 for both cell types, since in our laboratory, the alveolar bone cells were routinely 
cultured in FC1 and the long bone cells in FC3. This difference indicates that the lack of 
nodule formation in both alveolar bone cells and long bone cells in the present study 
might be a result of the serum used. In any case, the cells from both origins showed 
an equal lack of bone nodule formation.
We also investigated the osteoclastogenic potential of the cells derived from alveolar 
bone and long bone. Long bone-derived bone cells stimulated the formation of 
osteoclasts, while alveolar bone-derived cells did not, since numbers were comparable 
to the control condition without the bone cells added (Figure 4). Jaw and long bone-
derived cells from the bone marrow of mice have different osteoclastogenic potential, 
mostly due to the differences in the cellular composition of the bone marrow [11]. This 
might also be true for the population of cells isolated by the outgrowth of cells. In 
line with the increased osteoclast formation induced by long bone cells is the higher 
expression of RANKL, TNF-α, and IL-6 in long bone-PBMC co-cocultures, as well as in 
the increased RANKL/OPG ratio that favors osteoclast formation. Moreover, DC-STAMP 
is needed for cell-cell fusion [28] and was significantly higher expressed in the long 
bone-PBMC co-cultures in basic conditions, supporting our finding that the cells 
derived from long bones induced the formation of more osteoclasts. Interestingly, the 
supplementation of vitD3 seemed to downregulate the expression of DC-STAMP in both 
co-cultures of PBMCs with long bone cells and with alveolar bone cells (Supplementary 
Materials Figure S4), which correlates with a lower number of osteoclasts counted in the 
condition with vitD3. COX2 expression was significantly higher expressed in alveolar bone 
cells. COX2 is very important for fracture healing and plays a role in both osteoblast and 
osteoclast differentiation [29]. The inhibition of COX2 inhibits osteoclast formation [30], 
and this would suggest that the higher expression of COX2 would induce osteoclast 
formation, which is in contrast with our data.
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VitD3 is a biological component used in bone regeneration because it promotes 
the osteogenic differentiation of hMSCs by the upregulation of ALP and enhancing 
mineralization [31]. In the present study, the addition of vitD3 did not upregulate the 
cellular ALP, neither in alveolar bone cells nor in long bone cells. This might be because 
these cells are already in the osteogenic lineage and ALP is in general an early marker. 
Supplementation with vitD3 did enhance the expression of other osteogenic markers, 
such as OPN and DMP-1. VitD3 affects osteoclast formation by upregulating RANKL 
expression in human SaOS2 osteoblastic cells [32]. In contrast, supplementation with 
vitD3 to our human primary osteoblasts did not upregulate RANKL expression, and 
thereby did not enhance osteoclast formation.
Our results are measured in the absence of mechanical loading, which is not 
representative of the in vivo situation, wherein both the jaw as in the tibia, mechanical 
loading is present. Mechanical loading is known to have an enhancing effect on 
osteoblasts and a restrained effect on osteoclasts [33]. Adding mechanical loading to 
the cells would be interesting for further research on the differences in skeletal sites.
Due to donor to donor variability, some results had high SDs, which is observed 
more often when using human primary cells from multiple donors [16]. This high 
variance is inevitable, due to a higher degree of genetic differences between human 
individuals when compared to e.g., cells from inbred mouse or rat strains. Despite the 
variance between donors, many striking differences were observed in the present 
study. On the one hand, we would like to advocate such a comparison using cells 
from actual human donors, since it is likely closer to clinical reality when compared 
to using laboratory animals. On the other hand, and unfortunately, the cells derived 
from alveolar bone were not from the same donor as the cells derived from long 
bones, which would have made this study stronger. However, we can still see clear 
statistically significant differences between the cells derived from alveolar bone 
and long bone, which suggests that the two populations of cells are different. Many 
results were confirmed using different techniques, for instance, the osteoclasts were 
higher in long bone cultures, which was confirmed with the qPCRs of osteoclast 
genes expressed in these cultures.
In conclusion, the results of this present study showed that the cells derived from 
alveolar bone and long bone differ in their expression of osteogenic markers and their 
ability to induce osteoclast formation. We have to reject our hypothesis, as the results 
show that long bone cells instead of alveolar bone cells are more differentiated within 
the osteogenic lineage, and have increased osteoclastogenic potential. We show that 
cells from different skeletal sites, in this
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case, alveolar bone, and long bone, are different and react differently to osteotropic 
agent vitD3. These differences show that skeletal sites give rise to site-specific 
differences between the cells and indicate, that for the regeneration of specific sites, 
such as the alveolar bone, more research on site-specific tissue-engineering constructs 
is necessary.
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Figure S1. Graphs depict the osteogenic medium + vitD3 over the osteogenic medium at day 14 and 
day 21. (A) Effect of vitD3 on the RUNX2 expression. vitD3 had more effect on the long bone cells, which is 
significantly different on day 21. (B) Effect of vitD3 on the DMP-1 expression. vitD3 had more effect on long 
bone cells, which is significantly different on day 21. (C) Alizarin red staining for the calcium deposits. No 
calcium deposits were visible for both the alveolar bone cells and the long bone cells. Significance was 
measured using a 2-way ANOVA with Bonferroni post-tests. * = p < 0.05.
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Figure S2. Graphs depict osteogenic medium over the basic or the osteogenic medium + vitD3 over the 
osteogenic medium. (A) Osteogenic medium significantly increased the expression of IL-6 in the long bone 
cells. Supplementation of vitD3 upregulated the IL-6 expression in both the alveolar bone cells and the 
long bone cells. (B) Effect of vitD3 on the COX2 expression. VitD3 had more effect on the long bone cells, 
which is significantly different on day 21. Significance was measured using 2-way ANOVA with Bonferroni 
post-tests. * = p < 0.05.
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Figure S3. Graphs depicts the basic medium + vitD3 over the basic medium. Effect of vitD3 on the COX2 
expression. On day 14, vitD3 significantly upregulated the COX2 expression. Significance was measured 
using 2-way ANOVA with Bonferroni post-tests. * = p < 0.05.
Figure S4. Graphs depict the basic medium + vitD3 over the basic medium. (A) Effect of vitD3 on the DC 
stamp expression. Significance was measured using 2-way ANOVA with Bonferroni post-tests.
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Critical-size bone defects are a common clinical problem. The golden standard to 
treat these defects is autologous bone grafting. Besides the limitations of availability 
and co-morbidity, autografts have to be manually adapted to fit in the defect, 
which might result in a sub-optimal fit and impaired healing. Scaffolds with precise 
dimensions can be created using 3-dimensional (3D) printing, enabling the production 
of patient-specific, ‘tailor-made’ bone substitutes with an exact fit. Calcium phosphate 
(CaP) is a popular material for bone tissue engineering due to its biocompatibility, 
osteoconductivity, and biodegradable properties. To enhance bone formation, 
a bioactive 3D-printed CaP scaffold can be created by combining the printed CaP 
scaffold with biological components such as growth factors and cytokines, e.g., 
vascular endothelial growth factor (VEGF), bone morphogenetic protein-2 (BMP-2), 
and interleukin-6 (IL-6). However, the 3D-printing of CaP with a biological component 
is challenging since production techniques often use high temperatures or aggressive 
chemicals, which hinders/inactivates the bioactivity of the incorporated biological 
components. Therefore, in our laboratory, we routinely perform extrusion-based 
3D-printing with a biological binder at room temperature to create porous scaffolds 
for bone healing. In this method paper, we describe in detail a 3D-printing procedure 
for CaP paste with K-carrageenan as a biological binder.
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Introduction
Critical size bone defects caused by trauma, bone cancer, congenital defects, and 
overloading are a common clinical problem for which the standard treatment is 
autologous bone grafts [1,2]. These grafts are used in dentistry, oral and maxillofacial 
surgery, and orthopaedic surgery to stimulate the formation of new bone. However, 
current treatment options have significant limitations, i.e., autologous bone grafts are 
only available in limited volume, and a second surgery is needed for the harvesting 
procedure which is often associated with co-morbidity [3]. Importantly, autografts 
have to be manually adapted to fit the defect area. Unfortunately, the achieved fit 
is not precise, leaving lacunae in the contact area between the autograft and the 
defect border, which may impair bone healing and prolong the healing period. 
3D-printing offers a solution to this problem by enabling the reproducible production 
of clinically relevant scaffolds of precise dimensions, tailor-made to fit the defect, 
thereby facilitating bone regeneration.
CaP in scaffolds is often used for bone regeneration since the crystals in CaP-
containing scaffolds resemble the hydroxyapatite in natural bone, and the scaffolds 
are biocompatible. In addition, most forms of CaP dissolve chemically or are resorbed 
by osteoclasts in the human body, rendering the scaffolds bioresorbable [4]. 
Subsequently, the CaP can re-precipitate thereby transforming the scaffold surface, 
which stimulates the formation of bone [5,6].
3D-printing is a term that describes techniques that create objects in a layered 
fashion. Additive manufacturing techniques used in the medical field today include 
SLA, selective laser sintering, selective laser melting, and extrusion-based printing. 
3D-printing is based on computer-aided planning and 3D-design by using digital 
modeling and imaging technology (i.e., computer-aided design, or CAD). Therefore, 
shapes, geometries, and internal structures can be precisely defined. In addition, this 
method allows for the layer-by-layer build-up of the construct with proteins, drugs, 
and/or peptides, enabling localized characteristics to fit explicit functions of the 
construct at a specific site.
Several 3D-printing techniques can be used to fabricate CaP scaffolds. The two major 
types of printing used to print CaP are powder printing and extrusion-based printing. 
In extrusion-based printing, materials are extruded from a nozzle. This technique is 
gaining more and more interest as it can be carried out at room temperature and 
allows for the incorporation of biological components and/or cells [7–10]. Extrusion-
based printing of CaP is often based on the combination of particles with a polymer. 
4
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For example, hydroxyapatite particles can be combined with PCL and polylactic-co-
glycolic acid (PLGA) [11].
In powder printing, a layer is created by binding particles in a powder bed, either by 
sintering with a laser (SLS) or binding by drops of liquid (3D-powder printing) [12,13]. 
Both SLS and 3D-powder printing are used to bind CaP particles together, thereby 
creating porous and interconnected scaffolds. Unfortunately, these types of scaffolds 
are often not very strong, and need additional treatment, such as sintering or chemical 
treatment, to improve the strength of the scaffold [12,14].
Most CaP scaffolds have very good osteoconductive properties, i.e., they allow the 
bone to grow along their surfaces. To speed up the bone healing process, the scaffold 
should actively stimulate de novo bone formation and vascularization throughout 
the defect. Active stimulation can be achieved by adding biological components, 
such as bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth 
factor (VEGF), to scaffolds to enhance vascularization and bone formation [15,16]. 
The prime method to add biological components to a scaffold is adhesion to the 
scaffold’s surface. However, this method results in a burst release of the biomolecules 
in the first hours after incorporation into a defect site [17]. Such a burst release is 
often disadvantageous since high levels of biological factors are released following an 
uncontrolled release pattern during a short period of time, thereby possibly causing 
complications. A solution to this problem might be provided by the incorporation 
of components into the scaffold, resulting in a more sustained release pattern [18].
The printing of CaP for drug and growth factor delivery is challenging. Techniques 
using high temperatures or aggressive chemicals, such as SLS and 3D-powder 
printing, hinder the bioactivity of the incorporated biological components since 
cells and proteins that are active at body temperature lose their bioactivity at these 
high temperatures or are denatured by the chemicals. Extrusion-based printing 
is an option for achieving the incorporation of active growth factors, as this type 
of printing can operate at room temperature and use biological binders such as 
collagen and carrageenan. Carrageenan is derived from red seaweed and resembles 
the glycosaminoglycans (GAGs) in the extracellular matrix [19]. Other desirable 
properties are the interconnected porous network, elastic behaviour, and the ability 
to encapsulate cells [20,21]. The 3D-printing of CaP allows the incorporation of the 
biological component in the CaP and/or in the biological binder when it is performed 
at room temperature. Although several studies show printing methods for CaP at 
mild conditions [11,22–25], only a few studies show the incorporation of biological 
components such as growth factors [26,27]. Therefore, in our laboratory, we have 
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developed a method to print CaP at room temperature, permitting the incorporation 
of biologically active factors. The aim of the current methods paper is to describe 
a method to perform 3D-printing with CaP paste combined with the biological 
binder K-carrageenan under mild conditions in sufficient detail to serve as a basis for 
experiments by other laboratories.
Material and Methods
Production of Calcium Phosphate Paste
The CaP paste is produced by a precipitation reaction according to a modified version 
of a coating protocol described earlier [18,28]. In brief, a supersaturated CaP solution 
containing 684 mM NaCl (31434-1KG-M, Sigma-Aldrich, St Louis, MO, USA), 20 mM 
CaCl2·2H2O (102382, Merck Millipore, Darmstadt, Germany), 10.1 mM Na2HPO4·2H2O 
(106580, Merck Millipore, Darmstadt, Germany), and 200 mM HCl (100317, Merck 
Millipore, Darmstadt, Germany) is made.
The pH is increased from approximately 0.83 to 7.4 (range: 7.35–7.45) by adding 
TRIS (252859-500G, Sigma-Aldrich, St Louis, MO, USA). After adjusting the pH of the 
solution, incubation is performed overnight in a shaking water bath at 37 ◦C to allow 
CaP precipitation. After incubation, the precipitate (Figure 1A) is retrieved by removing 
(careful pouring) as much as possible of the supernatant. This precipitate is poured 
into sterile 50 mL tubes and centrifuged at 1000× g for 10 min. The supernatant is 
removed and discarded. Then PBS (14200-067, Thermo Fisher Scientific, Waltham, 
MA, USA) is added and the solution is mixed by shaking to wash the precipitate. 
After five repetitions of washing, centrifuging, and pouring off the supernatant, 
the last supernatant is removed. The result is a layer of CaP precipitate, from which 
the remaining moisture is removed by filtering with a 0.22 µm PES bottle top filter 
(431161, Corning Incorporated, Corning, New York, NY, USA) and an air pump until 
cracks appear in the CaP (Figure 1B, C). Before water removal with the filter, the CaP 
‘slurry’ obtained from 1 L CaP solution is approximately 13.87 g. After water removal, 
approximately 7.52 g of CaP paste remains (Figure 1D). After preparation, the CaP paste 
is stored in a syringe with a cap at room temperature. It is advised to use the paste 
within one week, as water evaporation will occur, thereby significantly influencing 
the structure of the paste.
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Figure 1. The calcium phosphate precipitation and calcium phosphate paste preparation. (A) CaP pre-
cipitate after overnight incubation; (B) Remaining moisture is removed from the CaP precipitate with a 
bottle top filter; (C) Cracks are formed in the CaP paste, indicating that water removal is sufficient to allow 
for printing; (D) CaP paste is ready to be used for 3D-printing.
Mixing
To print the CaP (with/without biological factors), a K-carrageenan (C1804, TCI, Tokyo, 
Japan) solution with a K-carrageenan concentration of 2.8% (wt/vol; kindly provided 
by Prof. S. Matsukawa, Tokyo) is mixed with the earlier prepared CaP paste in a 1:1.9 
(wt/vol) ratio. The K-carrageenan solution is weighed and heated to 37 ◦C in a water 
bath. The amount of CaP paste is determined with a 5- or 10-mL syringe and added to 
the K-carrageenan in a 7 mL plastic container. To a homogeneous mixture, sonication 
is performed using a sonicator (Vibra cell™, VCX 400, Sonics, Newtown, CT, USA) with 
the following settings: amplitude: 20%; pulse: alternating 1.0 s ‘on’ and 1.0 s ‘off’ for 
90 s. The mixture is then loaded into a printing cartridge, and ready to be printed.
Incorporation and Release of Biological Factors
To show the incorporation of biological factors in our scaffolds, bovine serum albumin, 
fluorescein conjugate (BSA-FITC; Molecular Probes, Eugene, OR, USA) is used as a 
model biological factor. To incorporate the model factor in the CaP paste, the BSA-
FITC is added to the precipitate after the washing steps. A total of 100 µL of a 10 mg/
mL BSA-FITC solution is added to approximately 10 mL precipitate and mixed with a 
spatula. Thereafter the standard protocol can be followed by drying the precipitate. 
To incorporate BSA-FITC in K- carrageenan, 10 µL of 10 mg/mL BSA-FITC is added to 
the warm (37 –C) K-carrageenan solution and mixed with a
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spatula. The standard protocol can be followed by adding the appropriate amount 
of CaP paste and mixing it with sonication. After 3D-printing, images are made with 
a Leica fluorescence microscope (Leica Microsystems, Wetzlar, Germany). For each 
condition (BSA-FITC in CaP paste, BSA-FITC in K-carrageenan, and control without 
BSA-FITC), a scaffold is placed in 2 mL of PBS to measure the release of BSA-FITC from 
the scaffold. Per condition, the release from 3 scaffolds is measured. At day 3, a 200 µL 
sample is taken and assayed, in duplicate, for fluorescence intensity at 520 nm with a 
Synergy HT® spectrophotometer (BioTek Instruments, Winooski, VT, USA).
Three-Dimensional Printing
For 3D-printing, a pneumatic-driven printing head of a 3D-Discovery printer (RegenHU, 
Fribourg, Switzerland) is used. Before placing the printing cartridge in the printhead, 
a 23 G (inner diameter: 0.33 mm) blunt needle (Cellink®, Gothenburg, Sweden) is 
attached to the cartridge. Scaffolds are designed using BioCad software (RegenHU, 
Fribourg, Switzerland), and a circular grid design with a diameter of 15 mm is used. 
Optimization of the system has resulted in the determination of optimal printing 
parameters as listed in Table 1. After scaffold printing, the K-carrageenan in the scaffold 
is cross-linked with an excess of 1 M KCl (104936, Merck Millipore, Darmstadt, Germany) 
for 30 min.
Table 1. The printing parameters used for the 3D-printing of CaP scaffolds with K-carrageenan as a binder.
Parameter Value
Initial height (mm) 0.5–0.80 (range)
Thickness (mm) 
 (range) Speed rate (mm/s)
0.25–0.40 
7
Pressure 1 (Bar) 0.5–2.0 (range)
Line space 2 (mm) 2.50
1 ‘Pressure’ is an adaptable parameter. When printing multiple scaffolds in a row, the pressure might have to be 
increased; 2 ‘Line space’ is the amount of space between the lines of the grid. Line space influences the number 
of lines used to fill up the grid.
Scanning Electron Microscope Imaging
For scanning electron microscope (SEM) imaging, samples are fixated overnight with 
a solution containing 4% paraformaldehyde, 1% glutaraldehyde, and 0.1 M sodium 
cacodylate. Samples are washed with distilled water, dehydrated with ethanol series, 
and dried overnight at room temperature. Samples are coated with gold using an 
Edwards Sputter Coater S150B (Edwards, Burgess Hill, England) and the images are 
made with a Zeiss EVO LS-15 scanning electron microscope (Zeiss, Oberkochen, 
Germany) with an accelerating voltage of 7 kV.
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3D-printing is used with increasing frequency to create patient-specific constructs 
based on computer-aided planning and 3D-design by using digital modeling and 
imaging technology. In this method paper, we describe a protocol for the printing of 
CaP at room temperature with the possibility of incorporating biological components.
The first step of the process entails the production of the CaP paste. We tested whether 
the sequence in which the salts are dissolved during the CaP production process 
affects the precipitation process. This appeared not to be the case. To estimate CaP 
mineral maturation in the precipitate, the Ca/P ratio was analyzed. The CaP ratio in 3 
samples is 1.46 ± 0.1 (mean ± SD). In the study by Leeuwenburgh et al. (2001), different 
layers are precipitated as coatings. One of these coatings uses the same salts in the 
supersaturated solution as we do in our study, and is described as an octacalcium 
phosphate coating [29]. In our protocol, higher ion concentrations are used, i.e., 5 times 
higher Na+ and Cl− ion concentration, 5.4 times higher HPO42− ion concentration, 
and 6.5 times higher Ca2+ concentration. The Ca/P ratio in our study is slightly higher 
compared to the Ca/P ratio of octacalcium phosphate, indicating the presence of 
calcium-deficient hydroxyapatite [30].
To characterize the CaP material, we used a scanning electron microscope (SEM). 
Under SEM, dried CaP particles appear as irregular microspheres with plate-like crystals 
(Figure 2A). When the K-carrageenan is mixed with the CaP paste and dried (Figure 
2B), fewer plate-like crystals are present. The exact crystal structure of the CaP after 
printing with K-carrageenan remains to be determined, but the crystal structure is 
likely amorphous [31]. We use CaP paste rather than dry particles for printing and do 
not dry the 3D-printed scaffolds after printing, as this causes excessive shrinking and 
possibly structural damage to the constructs. From 1 L ion solution, 7.5 g of CaP paste 
is produced. When all the water is evaporated from 7.5 g paste, approximately 1.4 g 
of CaP particles is obtained. The paste thus contains approximately 4.4 g of water per 
gram of CaP precipitate.
559887-L-bw-Kelder
Processed on: 6-5-2021 PDF page: 87
87
Method for printing bioactive calcium phosphate-based scaffolds 
Figure 2. Scanning electron microscopy. (A) CaP; (B) CaP with K-carrageenan. Magnification: 5000×, 
Scalebar: 1 µm.
Here K-carrageenan is used as a biological binder. Other materials, e.g., bioink from 
Cellink® or a silanized hydroxypropylmethylcellulose hydrogel, can be used as well. 
The bioink from Cellink® is composed of nanofibrillated cellulose and alginate. The 
nanofibrils are morphologically similar to collagen [32], one of the main components 
in the bone matrix. The bioink is optimized for extrusion-based printing. Silanized 
hydroxypropylmethylcellulose hydrogels can be mixed with BCP granules [33] and, 
therefore, can be mixed with CaP. Moussa et al. (2017) show that adipose stem cells are 
viable inside these hydrogels [34]. We use K-carrageenan because of its resemblance 
to native glycosaminoglycans and proven biocompatibility [35,36].
We routinely print scaffolds with a diameter of 1.5 cm and strands of 1–1.5 mm in width 
(Figure 3). Scaffolds printed in consecutive order vary somewhat in dimensions. We 
measured the strand width of 3 scaffolds printed in one experiment. The width of the 
strands varied from 0.8 to 1.6 mm. The average strand width (measured at 10 different 
points: 5 vertical and 5 horizontal) of the 3 scaffolds was respectively 1.3, 1.2, and 1.0 
mm. The average pore size was also measured, which was respectively 0.31, 0.39, and 
0.55 mm2. In our experience, scaffolds printed on consecutive days had the same 
dimensions. The maximum printing volume is 130 mm × 90 mm × 60 mm.
Figure 3. The 3D-printed scaffold. Scale in centimeters.
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For the printing of viscous composites, optimization steps are needed. For example, 
the nozzle can penetrate the previously printed layers, which is unfavourable. This 
problem may be solved by adopting the printing parameters. When the layer thickness 
(setting of the printer) is increased, the distance the nozzle goes up with every layer 
increases, thereby solving the problem. Small incremental steps (0.01 mm) are 
used until the needle stops penetrating the previous layers. In addition, increasing 
the parameter initial height can also help solve the problem. We tend to print at a 
pressure of 1 Bar, which creates strands between 1 and 1.5 mm as described above. 
By decreasing the pressure, it is possible to create thinner strands, although this 
might lead to a disruption of the continuity of the printing process. Another option 
to decrease the strand thickness is to increase the initial height of the nozzle, as the 
strands are more stretched while being printed. The advantage of using thinner 
strands is that it provides increased scaffold porosity, but the disadvantage is that 
the strands might be mechanically weaker. The thinnest strands that we have obtained 
using CaP paste and K-carrageenan have a thickness of 0.75 mm.
The 3D-printing method described in this paper is performed at room temperature 
and without aggressive solvents, allowing biological components to be incorporated 
into the CaP and/or in the K-carrageenan. BSA-FITC is used as a model to show the 
incorporation of biological components in CaP. In Figure 4, a fluorescent signal is 
visible when BSA-FITC is incorporated into the CaP paste (A), and in the K-carrageenan 
(B). The materials are not autofluorescent as no fluorescent signal is visible in the 
control sample (C). The release of BSA-FITC from the scaffolds is measured after 3 
days. The cumulative BSA-FITC release from the scaffolds incorporated in the CaP 
paste and, in the K-carrageenan is determined (Figure 5). The BSA-FITC release from 
K-carrageenan is less than that from CaP paste. This might be explained by the fact 
that the total amount of BSA-FITC incorporated in CaP paste was 10 times higher than 
in K-carrageenan. This difference in the amount used was based on the expectation 
that more BSA-FITC would be lost during its incorporation in CaP paste. We show 
that biological factors can be incorporated in both CaP paste and, in a K-carrageenan 
solution and that these factors are released from the scaffolds. We estimate that 
approximately 0.02% of the incorporated BSA-FITC is released from CaP/K-carrageenan 
scaffolds after 3 days.
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Figure 4. The fluorescent images of incorporated bovine serum albumin, fluorescein conjugate.
(A) CaP/K-carrageenan scaffold with BSA-FITC incorporated in the CaP paste; (B) Scaffold with BSA-
FITC incorporated in the K-carrageenan solution; (C) Control scaffold without BSA-FITC incorporated. 
Magnification: 4×.
Figure 5. The release of incorporated BSA-FITC. From a CaP scaffold with BSA-FITC incorporated in the 
CaP paste, a scaffold with BSA-FITC incorporated in the K-carrageenan solution, and a control scaffold 
without BSA-FITC incorporated. Normalized for the volume of the scaffolds. The significance is compared 
to the control scaffold, ** is p < 0.01 and *** is p < 0.001.
Liu et al. (2001) have tested the release of co-precipitated BSA from CaP particles. 
They found that only 0.3% of the incorporated BSA was released during the first 4 h, 
which increased to 0.85% after 6 days [18]. It has been reported that the release of 
BMP-2 increases due to the resorption of the material by cells [28]. Our precipitation 
protocol is based on the protocol of Liu et al. but the release of biological factors from 
the printed end product is likely to be different from the particles as described by 
Liu et al. (2001) as we use the precipitated CaP as a paste rather than as dry particles, 
and we combine the CaP with carrageenan. By experimenting with incorporating 
biological components in the K-carrageenan and/or in CaP paste, favorable release 
kinetics can be tailored.
For eventual clinical purposes, it is important that the whole scaffold production 
process can be performed under sterile conditions. The CaP paste can be produced 
in a sterile manner since a CaP solution and a TRIS solution can be made separately 
and filtered with a Millipore filter unit of 0.22 µm. After filtering, the solutions are 
mixed and incubated overnight in a shaking water bath at 37 ◦C. The K-carrageenan 
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can be sterilized by heating till 85 ◦C for 3 h and both the mixing and the 3D-printing 
can be done under sterile conditions, for example, in a cleanroom. Taken together, we 
have provided a detailed protocol for the printing of CaP-carrageenan hybrid scaffold 
which can be used as a base by other labs to establish their own 3D-printing protocol.
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Recently we described a method for the 3D-printing of a bioink consisting of a 
calcium phosphate paste and κ-carrageenan, with the possibility to incorporate 
active biological components, for the healing of critical-sized bone defects. In this 
study, we assessed whether bioinks made of this mixture, either or not enhanced 
with 1,25(OH)2vitD3 (vitD3), are likely to be clinically relevant. To do this, printability, 
compressive stiffness, and bioactivity of CaP-based bioinks mixed with 2.8%, 3.8%, or 
4.8% (wt/vol) κ-carrageenan were measured. Furthermore, the human osteosarcoma 
cell line U2OS was cultured in the presence of constructs made with the bioink, either 
or not containing 125 ng vitD3, and cytotoxicity, cell viability, and cytokine release 
were measured up to 7 days. Constructs (15 mm diameter, 3 mm height, 1 mm strand 
thickness) could be consistently printed with 2.8% and 3.8% κ-carrageenan but not 
with 4.8% κ-carrageenan solution. The compressive stiffness of solid cylindrical 
constructs (10.7 mm diameter) made with 2.8% and 3.8% κ-carrageenan was very 
similar, respectively 170 ± 45 kPA and 212 ± 77 kPA. The bioink was not cytotoxic and 
did not have a negative effect on the proliferation of U2OS cells. The gene expression 
of CYP24a1 was upregulated by conditioned medium of constructs with vitD3, 
indicating that the vitD3 is released and bioactive. Furthermore, the bioink led to an 
increased release of RANKL and reduced OPG released by the cells, independent of 
adding vitD3. These results show that constructs made of CaP paste and κ-carrageenan 
can be consistently produced, are not fragile or cytotoxic, allow the release of active 
biological factors, and thus show promise for future use in a clinical setting.
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Introduction
The intrinsic healing capacity of bone is compromised when a defect is of a critical 
size. Therefore, critical size bone defects remain a clinical challenge. Often autologous 
bone grafts, taken from the patient, are used for the treatment of this kind of defects 
[1,2]. This treatment can have adverse effects, such as donor site morbidity and pain, 
and especially trauma patients may have limited availability of donor bone [3]. Bone 
tissue engineering constructs may be used as an alternative treatment option, thereby 
avoiding these disadvantages. To aid the healing of bone, such constructs would 
preferably have both osteoconductive properties [4] i.e. conducts bone growth along 
its surface, and osteoinductive properties [5] i.e. induce de novo bone formation [3].
For bone tissue engineering, calcium phosphate (CaP) containing materials are 
frequently used for the generation of scaffolds, since CaP-based scaffolds resemble the 
contents of the apatite in natural bone, and CaP-containing materials generally have 
osteoconductive properties [6]. To improve the osteoinductive properties, CaP-based 
constructs can be enhanced with biological components such as Vascular endothelial 
growth factor (VEGF), Bone morphogenetic protein 2 (BMP-2), and 1,25(OH)2 vitamin 
D3 (vitD3), to stimulate bone formation and blood vessel formation[7]. VitD3 is the 
active form of vitamin D and holds promise for the use in bone tissue engineering, 
because it stimulates the osteogenic differentiation of human bone marrow stromal 
cells (hMSCs) [8]. In addition, vitD3 is relatively safe, works at low doses, and is relatively 
cheap. Adding vitD3 to tissue engineering constructs may help the healing of large 
bone defects.
Tissue engineering constructs based on CaP-containing scaffold can be fabricated in 
several ways, such as solvent casting/ particulate leaching [9], electrospinning [10], 
and 3D-printing [11]. Recently, 3D-printing gained more interest for the production 
of tissue engineering constructs, as it permits the rapid fabrication of patient-specific 
scaffolds that will fit the defect perfectly, enabling maximum contact area between 
the construct and the native bone. 3D printed constructs can be locally functionalized 
with biological components to fit particular requirements at a specific anatomical site. 
The 3D-printing of CaP-based materials can be performed with several 3D-printing 
techniques, such as powder printing or extrusion-based printing [12,13]. With the 
first technique, CaP particles are fused, either by a laser or by a liquid binder, and 
in the second technique, fluid CaP-containing material is extruded from a nozzle. 
These techniques often use high temperatures or aggressive chemicals, hindering 
the incorporation of biological components.
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We have previously described a method for the 3D-printing of a bioink consisting 
of a CaP paste mixed with κ-carrageenan, with the possibility to incorporate active 
biological components [14]. In the present study, we assessed whether constructs 
made with this bioink and enhanced with vitD3 are potentially clinically relevant, 
by measuring the possibility to consistently print cylindrical objects, quantifying 
compressive stiffness of cylinders cast with the bioink, and determining the response 
of human osteoblast-like cells to leachables released from the ink.
Material and Methods
CaP paste production
Production of the CaP paste is achieved by a precipitation reaction described earlier 
[14]. In short, a sterile supersaturated CaP solution containing 684 mM NaCl (31434, 
Sigma-Aldrich, St Louis, MO, USA), 20 mM CaCl2·2H2O (102382, Merck Millipore, 
Darmstadt, Germany), 10.1mM Na2HPO4·2H2O (106580, Merck Millipore, Darmstadt, 
Germany), and 200 mM HCl (100317, Merck Millipore, Darmstadt, Germany) was 
made and filtered with a 0.22 µm sterivex filter (Millipore, Burlington, MA, USA) for 
sterilization. The pH was adjusted to 7.4 ± 0.5 by the addition of a sterile TRIS (Sigma-
Aldrich, St Louis, MO, USA) solution. Thereafter, the solution was incubated overnight 
in a shaking water bath at 37°C to allow for precipitation. The precipitate was washed 
five times with sterile PBS and the remaining moisture was removed by filtering with 
a 0.22 µm PES bottle top filter (431161, Corning Incorporated, Corning, New York, NY, 
USA) and an air pump resulting in a CaP paste.
Κ-carrageenan
Κ-carrageenan is a compound derived from red seaweed and resembles the 
glycosaminoglycans (GAGs) in the extracellular matrix [15]. Sodium-type κ-carrageenan 
(Tokyo Chemical Industry Co., Ltd. Tokyo, Japan) is dialyzed against NaCl solution 
and subsequently against deionized water to obtain Na+ type carrageenan solution. 
The Na+ and K+ concentrations, analyzed by inductively coupled plasma atomic 
emission, are 0.4% and 0.11%, while no Mg2+ or Ca2+ are detected in the dialyzed 
sample. Κ-carrageenan solutions with concentrations of 2.8%, 3.8%, and 4.8% (wt/
vol) were prepared by dissolving freeze-dried κ-carrageenan (kindly provided by Prof. 
S. Matsukawa, Tokyo) overnight in milliQ in a water bath at 37°C. The solutions were 
sterilized by boiling in a closed container for 1 hour. The solutions were stored at 4°C 
and warmed up to 37°C before use.
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Production of cylinders
To test the compression modulus, activity of released vitD3, cytotoxicity of the bioink, 
and effect of the bioink on human osteoblast-like cells, we used cylinders prepared 
with the bioink. The cylinders had a diameter of 10.78 ± 0.16 mm and were 4.55 ± 
0.19 mm in height, and were prepared as follows: The CaP paste and κ-carrageenan 
solutions were mixed in a 1:1.9 (wt/vol) ratio. For cylinders containing vitD3, 125 ng 
vitD3 (Sigma, stock: 30µM in 100% ethanol, stored at -80°C, in the absence of light) 
per cylinder was added to the κ-carrageenan before mixing. One cylinder consists of 
approximately 0.6 ml of bioink. The sample was sonicated to ensure a homogeneous 
mixture. Sonication was performed at room temperature using a sonicator (Vibra 
cell™, VCX 400, Sonics, Newtown, CT, USA) with the following settings: amplitude: 20%; 
pulse: alternating 1.0 sec ‘on’ and 1.0 sec ‘off’ for in total 90 s. The mixture was then 
collected in a syringe and pushed into polyvinylsiloxane molds with a thickness of 4 
mm and 10 mm in diameter. Sterile glass slides are used to equalize the mixture in the 
molds. Cylinders were crosslinked using an excess of sterile 1M KCl (Merck Millipore, 
Darmstadt, Germany) for 45 minutes. After this incubation, the KCl was removed and 
the cylinders were washed with sterile PBS. The cylinders were carefully pressed out 
of the molds with a spatula and were directly used.
Printability
The printability of bioinks containing 2.8%, 3.8%, or 4.8% κ-carrageenan solutions 
were compared with respect to the following parameters: consistent strand thickness, 
consistent pore size, and the number of failed constructs. Scaffolds were printed 
according to the method described by Kelder et al [14]. In short, CaP paste was mixed 
with κ-carrageenan in a 1:1.9 (wt/vol) ratio. The mixtures were loaded to a cartridge of 
a 3D-Discovery printer (RegenHU, Fribourg, Switzerland) and printed with a 23G (inner 
diameter: 0.33 mm) blunt needle. A simple construct was printed with an intended 
diameter of 15 mm and a strand thickness of 1 mm. We measured the diameter, strand 
size, and pore size by counting pixels in digital images of known resolution. The printer 
settings were fine-tuned for each batch. For each κ-carrageenan concentration, we 
printed 5-6 scaffolds, on two separate occasions.
Compression modulus
To measure the compression modulus of the bioink we used cylinders that were 
prepared as described above in “production of cylinders”. Cylinders were prepared 
and then stored in PBS for 24 hours. Compression was measured using a universal 
testing machine (Instron 6022, Instron, Norwood, MA, USA) with a loading cell of 50 
N and a speed of 1.0 mm/sec.
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The compression elastic modulus (E) was calculated in the linear area between 30 – 90 
sec, using the following equation: 
Where σ= stress; ε= strain; F=Force; A=Area; ΔL= change of length; L0= initial length.
Cytotoxicity of the bioink
To measure the cytotoxicity, 2.0 × 105 human osteosarcoma-derived (U2OS) cells were 
seeded one day before the experiment (day -1) on the bottom of a 12-well plate, and 
cultured in basic medium consisting of minimum Essential Medium Alpha (α-MEM; 
Thermo Fisher Scientific, Waltham, MA, USA) without phenol red, supplemented with 
1% fetal clone I serum (FCI, HyClone, Logan, UT, USA), and 1% Antibiotic Antimycotic 
Solution 100× (PSF; Sigma, St Louis, MO, USA). At day 0, cylinders with and without 
vitD3 are placed in inserts (pore size 3.0 µm; Greiner Bio-one, Alphen aan de Rijn, the 
Netherlands) above the cells with 0.5 ml of medium in the insert and 1.5 ml of medium 
in the well. After 24 hours, the medium in the inserts was collected and mixed with 
the medium in the well and the cytotoxicity was measured using ToxiLight™ bioassay 
kit (Lonza, Bazel, Switzerland) according to the manufacturers’ protocol.
Cell viability
The viability of U2OS cells was measured with AlamarBlue™ Cell viability reagent 
(Invitrogen, Carlsbad, CA, USA). Alamar blue conversion was measured at day 0, day 2, 
day 5, and day 7. For each time point, 3.0 × 104 cells per well (12-well plate) were seeded 
one day before the experiment (day -1) in basic medium, consisting of α-MEM (no 
phenol red) supplemented with 10% FCI and 1% PSF. Tissue culture inserts containing 
cylinders produced of the bioink (with or without vitD3) were placed above the cells at 
day 0 with 0.5 ml of medium in the insert and 1.5 ml of medium in the well. To measure 
the Alamar blue conversion, the cylinders and medium were removed, and 2 ml of 
medium containing 10% AlamarBlue reagent was added to the wells and incubated for 
4 hours at 37˚C. As a negative control, the same medium with 10% AlamarBlue reagent 
was incubated in an empty well. After incubation, 100 µl (in duplicate) was taken from 
each sample, transferred to a black 96-well plate and fluorescence was measured at 
530-560 nm with Synergy HT® spectrophotometer (BioTek Instruments, Winooski, VT, 
USA). Medium without cells and with 10% AlamarBlue reagent was autoclaved to fully 
reduce the AlamarBlue reagent and used as a positive control. Samples are presented 
as a percentage of the positive control.
559887-L-bw-Kelder
Processed on: 6-5-2021 PDF page: 101
101
Behavior of vitamin D3 containing, 3D-printed, calcium phosphate scaffolds 
DNA content and Alkaline Phosphatase activity
One day before the experiment 3.0 × 104 U2OS cells were seeded/well in a 12 well 
plate and cultured in basic medium, consisting of α-MEM (without phenol red) 
supplemented with 10% FCI and 1% PSF. Tissue culture inserts containing bioink 
cylinders (with or without vitD3) were placed above the cells at day 0 with 0.5 ml 
of medium in the insert and 1.5 ml of medium in the well. At day 0, day 2, day 5, 
and day 7, cells were washed with PBS and lysed with 200 µl of Milli-Q water and 
frozen at -20°C for storage. After three freeze-thaw cycles, samples were collected 
by scraping followed by a centrifuging step to get rid of debris. DNA content was 
measured using a Cyquant cell proliferation kit (Molecular probes, Eugene, OR, USA) 
according to manufacturers’ protocol. ALP was measured in cell lysate according to the 
method described by Lowry [16] using 4-nitrophenyl phosphate disodium salt at pH 
10.3 as a substrate for ALP. Absorbance was measured at 405 nm with the Synergy HT® 
spectrophotometer. To correct for cell number, ALP measurements were normalized 
for DNA content.
Activity of released vitD3
The activity of the released vitD3 was determined by quantifying the gene expression 
of CYP24a1 in U2OS cells. CYP24a1 expression is strongly upregulated in osteoblasts 
when bioactive vitD3 is available. Cylinders with or without vitD3 were placed in 2 
ml of basic culture medium, as described above, for 24 hours. The conditioned 
medium was collected and placed on top of U2OS cells seeded at 5.0 × 104 cells 
per well in a 12 well plate. The next day, total RNA was isolated with TRIzol® reagent 
(Invitrogen) following the manufacturer’s protocol. The concentration and purity of 
RNA were measured using a Synergy HT® spectrophotometer and 750 ng RNA was 
reverse-transcribed to cDNA using RevertAid™ First Strand cDNA Synthesis Kit 1612 
(Fermentas, St. Leon-Rot, Germany) according to the manufacturer’s protocol. For 
the qPCR reaction, cDNA was diluted 5× and 1 µl was used, together with 3 µl PCR-
H2O, 0.5 µl (20 µM) forward primer (5’ CAAACCGTGGAAGGCCTATC 3’), 0.5 µl (20 µM) 
reverse primer (5’ AGTCTTCCCCTTCCAGGATCA 3’), and 5 µl 2x LightCycler® 480 SYBR 
Green I Mastermix (Roche Diagnostics). The values of Cyp24a1 were normalized to 
hypoxanthine phosphoribosyl transferase (HPRT, FWRD: 5’ GCTGACCTGCTGGATTACAT 
3’ REV: 5’ CTTGCGACCTTGACCATCT 3’) following the comparative cycle threshold (ΔCt).
Legendplex
One day before the experiment (day -1), cells were seeded at a density of 3.0 × 104 
cells per well in a 12-well plate in basic medium consisting of α-MEM (no phenol 
red) supplemented with 10% FCI and 1% PSF and cultured up to 7 days. Inserts with 
cylinders (with or without vitD3) were placed above the cells at day 0 with 0.5 ml of 
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medium in the insert and 1.5 ml of medium in the well. The medium was collected at 
day 0, day 2, day 5, and day 7. Secreted Osteoprotegerin (OPG), Osteopontin (OPN), 
Receptor activator of nuclear factor kappa-Β ligand (RANKL), Tumor Necrosis Factor 
Alpha (TNF-α), and Interleukin-6 (IL-6) were quantified according to manufacturer’s 
protocol in the conditioned mediums using LEGENDplex™ (BioLegend, San Diego, CA, 
USA) according to the manufacturers’ instructions on a BD Accuri™ C6 FACS machine. 
The settings suggested by BioLegend were used and the analysis was performed with 
the software provided by the manufacturer.
Statistics
Data were obtained from 6 separate cultures of U2OS cells combined with constructs 
made of 6 fresh batches of bioink (n=6). Data are presented as mean + standard 
deviation (SD). A t-test was conducted to test for the statistical differences between 
2.8% and 3.8% κ-carrageenan constructs in diameter, strand thickness, pore size, 
and compressive modulus. For the statistical difference between the 3 groups 
in cytotoxicity, a one-way ANOVA with a Tukey post hoc test was used. Statistical 
comparisons of the experiments with multiple time points were done using a 2-way 
ANOVA with Bonferroni post-tests. With time and ‘condition’ used as the dependent 
variables, the p values of < 0.05 were considered significantly different. The analyses 
were performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA).
Results
Reproducible constructs can be 3D-printed with 2.8% and 3.8% κ-carrageen-
an but not with 4.8% κ-carrageenan.
In order to assess the printability of the bioink consisting of a mixture of CaP paste 
and κ-carrageenan, we printed simple scaffolds and measured the diameter, strand 
thickness, and pore size (Figure 1). In total 11 constructs were printed per concentration. 
For both 2.8% and 3.8% κ-carrageenan, 3 out of 11 constructs were incomplete/
incorrect and were not included in the measurements. Printing with a mixture made 
with 4.8% κ-carrageenan was not feasible, due to the lower viscosity of the material, 
which caused the flowing of the strands. For this reason, only data of scaffolds printed 
with 2.8% and 3.8% κ-carrageenan are shown. The printing settings were optimized 
for each batch. There was no difference in diameter between constructs made with 
2.8% or 3.8% κ-carrageenan, but the spread of the data seems wider in 3.8% (Figure 
1B). Also, the strand thickness is similar between the 2 mixtures, but here the spread 
seems larger in constructs printed with 2.8% κ-carrageenan (Figure 1C). There are 
significantly larger pores in the construct printed with 3.8% κ-carrageenan (Figure 1D).
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Figure 1. Printability of constructs printed with 2.8% and 3.8% κ-carrageenan. Measurements of 
diameter, strand thickness, pore size of constructs printed with 2.8% and 3.8% κ-carrageenan. (A) Simple 
3D-printed construct. (B)The average diameter of 3D-printed constructs was similar in both groups (C) 
average strand thickness was also similar in both constructs made with 2.8% κ-carrageenan and 3.8% 
κ-carrageenan (D) Average pore size was significantly higher in constructs printed with 3.8% κ-carrageen-
an. Significance was determined using a t-test. * p<0.05.
Adding vitD3 to the bioink has an anti-cytotoxic effect.
To be clinically applicable, the mixture of CaP paste and κ-carrageenan should be stiff 
enough to be placed in non-load bearing defects and should not negatively affect 
the cells surrounding scaffolds. The apparent compressive stiffness was determined 
by calculating the apparent compression elastic modulus of the bioink when cast into 
a solid cylindrical shape (Figure 2A). The compressive modulus was slightly higher in 
constructs made with 3.8% κ-carrageenan, namely 212 ± 77 kPA compared to 170 ± 
45 kPA for 2.8% κ-carrageenan, but this is not significant. Because the strand thickness 
appears to be more homogeneous and the compressive modulus seems marginally 
higher, we continued our experiments with constructs made of bioink containing 
3.8% carrageenan. When the cytotoxicity was assessed by ToxiLight™ bioassay kit, no 
differences in relative luminescence were found between the control (cells incubated 
on plastic only), and those exposed to cylindrical constructs (3.8% κ-carrageenan). 
Interestingly, relative luminescence was significantly lower in cells exposed to 
constructs with vitD3 compared to those exposed to samples without vitD3 (Figure 2B). 
Adding vitD3 reduced the luminescence by an average of 9.7 percent. The morphology 
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of cells cultured in the presence of cylinders with or without vitD3 seems similar to that 
of cells cultured on plastic without cylinders (Figure 2C,2D, 2E). Interestingly, the wells 
containing cylinders without vitD3 seemed to contain more round cells, reminiscent 
of dividing cells, compared to the condition without vitD3. Alamar blue, together with 
DNA levels, was used to assess cell viability and proliferation (Figure 2F,2G). Between 
day 0 and day 7, Alamar blue conversion increased 9.5-fold in the control, 8.8-fold in 
cells cultured with cylinders with vitD3, and 6.6-fold in cells cultured with cylinders 
without vitD3. At day 5 the cells cultured on plastic convert significantly more Alamar 
blue than cells cultured together with constructs (with and without vitD3). Also, 
conversion of Alamar blue was significantly lower in cell cultures grown in the presence 
of a construct without vitD3 compared to cultures grown with constructs with vitD3. 
At day 7, the cells cultured on plastic still converted significantly more Alamar blue 
than the cells cultured together with constructs with no vitD3, but do not differ with 
the cells cultured together with cylinders with vitD3. DNA levels increased on average 
3.2-fold between day 0 and day 7. There are no differences in DNA levels between the 
conditions at any time point (Figure 2G).
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Control
   + vitD3      -vitD3
   
Figure 2. Compressive modulus and cytotoxicity of the bioink.
(A) Compressive modulus of cylinders made with 2.8% and 3.8% κ-carrageenan was similar in both groups. (B) 
Cytotoxicity was measured by ToxiLight™ of U2OS cells cultured on plastic and together with cylinders with or 
without vitD3. (C, D, E) morphology of cells on plastic and together with cylinders with and without vitD3. Cylinders 
without vitD3 are more cytotoxic than cylinders made with vitD3. Scale bars represent 200 µm (F) Alamar blue 
levels of cells on plastic and together with cylinders with and without vitD3. (G) DNA levels measured of cells on 
plastic and together with cylinders with and without vitD3. * p<0.05, ** p<0.01, *** p<0.01
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VitD3 is released from the bioink and is bioactive.
To have a biological effect, the released vitD3 from the cylinders needs to be bioactive. 
Cells cultured for 1 day with medium incubated with cylinders made from bioink 
containing vitD3 had on average a 165-fold higher relative gene expression of Cyp24a1 
than cells cultured with conditioned medium from cylinders without vitD3 (n=2).
The bioink increased the release of OPN, RANKL, and OPG compared to the 
control.
To be clinically relevant, the constructs should stimulate the cells adjacent to this 
material to differentiate towards bone and/or produce factors that stimulate bone 
remodeling. To measure osteogenic differentiation, cellular ALP activity, and OPN 
released in the culture medium was measured. The ALP activity (Figure 3A) was very 
similar at all time points and no differences were apparent between the groups. The 
released OPN (Figure 3B) increased significantly up to day 5 for all conditions. At day 
7 the released OPN was higher in the conditions containing a construct. This apparent 
effect was significant in the condition with a construct without vitD3. To measure the 
ability of the cells to contribute to osteoclast formation, the release of IL-6, TNF-α, 
RANKL, and OPG by the cells was also measured in the medium. The amount of IL-6 
released was similar between all the groups except at day 5, where the concentration 
was significantly higher in the medium taken from cells grown on plastic compared 
to the conditioned medium taken from cells grown in the presence of constructs 
(figure 3C). Cells exposed to each of the three culture conditions released a similar 
amount of TNF-α at all time points (Figure 3D). The amount of RANKL released was 
higher in conditioned medium taken from cells grown in the presence of constructs 
than in medium taken from cells grown on plastic (Figure 3E). This was significant 
for the constructs with vitD3 at day 2 and day 5. At day 7, this was significant for both 
conditions with a construct. The amount of released OPG was ~ 15-times higher than 
the amount of released RANKL at day 0, this increased in time. At day 5 and day 7, the 
amount of OPG released was significantly higher in medium taken from the control 
than in medium taken from cells grown in the presence of constructs (Figure 3F). 
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Figure 3. ALP activity and released cytokines of U2OS cells cultured with or without the bioink.
All experiments were done at day 0, day 2, day 5, and day 7 in samples with cells cultured on plastic, and cells 
cultured on plastic together with cylinders (3.8% κ-carrageenan) with or without vitD3. (A) Cellular ALP, as a 
measure for osteogenic differentiation, was corrected for DNA levels and is similar in all conditions. (B) The 
released OPN was significantly higher in the condition with a construct without vitD3 compared to plastic at 
day 7. (C) Released IL-6 was significantly higher in U2OS cells cultured on plastic at day 5. (D) Released TNF-α 
was similar in all conditions at all time points. (E) The released RANKL was significantly higher in the condition 
with a construct with vitD3 at all time points. (F) Released OPG was significantly higher when cells were cultured 








In this study, we evaluated the potential clinical applicability of a bioink consisting of a 
mixture of CaP paste and k-carrageenan, enhanced with biological component vitD3. 
We chose vitD3 since vitD3 stimulates osteogenic differentiation of mesenchymal stem 
cells when released from tissue-engineered constructs, as we have shown recently 
[17]. We found that bioinks containing 3.8% k-carrageenan were printable, released 
active vitD3 did not inhibit the proliferation of U2OS cells, and led to increased release 
of soluble RANKL and strongly reduced OPG released by these cells. Taken together, 
our results suggest that constructs made of CaP paste and κ-carrageenan could give 
rise to 3D-printed scaffolds that are clinically relevant.
Although the compression elastic modulus of cylinders cast with the bioink as used 
in the present study is not in the same range (104-times lower) as the compression 
elastic modulus of bone [18], it is similar to other bioinks used for 3D-bioprinting, 
e.g. based on alginate and gelatin [19,20]. The bioink is strong enough to contain its 
shape and can be carefully picked up and handled by a surgeon to be placed in a 
non-load-bearing defect. Initial stabilization e.g. with metal plates will be necessary. 
Engler et al., show that stiffer matrices (~ 40 kPa) direct mesenchymal stem cells into 
the osteogenic lineage compared to softer matrices (between 7- 17 kPa) which direct 
the cells towards the myogenic lineage and even softer matrices (between 0.1 and 1 
kPa) which direct the cells towards the neurogenic lineage [21]. Since the compression 
elastic modulus of our material is higher than 40 kPa, we speculate that this may direct 
stem cell differentiation towards the osteogenic lineage.
The construct that contains vitD3 appears to be less toxic for the cells than tissue culture 
plastic, although this effect is not significant (n=4). We speculate that the adenylate 
kinase, used as a measure for cytotoxicity, is partly absorbed by the bioink, or that 
the construct might already be chemically dissolving, thereby somehow interfering 
with the measurement. This would mean that the release of adenylate kinase from 
cells in the presence of constructs is underestimated, and the combination of CaP 
and k-carrageenan may actually be slightly cytotoxic. This would be in line with the 
results from Lim et al., who show that higher concentrations of κ-carrageenan in 
gelatin/ κ-carrageenan scaffolds lead to lower cell viability of fibroblasts [22]. In any 
case, adding vitD3 to the construct seems to have a protective effect on the cells. This 
is also visible in Alamar blue data. This positive effect of vitD3 on cell viability has been 
reported for the human cell line HepG2 [23].
559887-L-bw-Kelder
Processed on: 6-5-2021 PDF page: 109
109
Behavior of vitamin D3 containing, 3D-printed, calcium phosphate scaffolds 
VitD3 can induce osteogenic differentiation in stem cells [24]. The results in this 
study show no differences in ALP activity and no effect of cylinders made of bioink 
containing vitD3 vs. those without vitD3 on the release of OPN by U2OS cells. It might 
be that U2OS cells do not respond to the vitD3 with an increase in differentiation. Luo 
et al. show that U2OS cells have a low basal ALP level and do not respond to BMPs 
with an increase in osteogenic differentiation [25]. U2OS were capable to detect and 
respond to vitD3 since CYP24a1 expression did go up by 165-fold. To better assess the 
effect of the bioink on osteogenic differentiation another cell source might be more 
suitable, such as hMSCs or primary human bone cells.
Interestingly, the bioink enhanced the release of RANKL by U2OS cells, especially the 
bioinks containing vitD3. RANKL plays an important role in osteoclastogenesis and can 
be induced by vitD3 [26]. This could indicate that the bioink enhances the stimulation 
of osteoclastogenesis by osteoblasts, especially since incubation with cylinders made 
of the bioink also reduced OPG expression by U2OS cells by almost 100-fold. This 
shows that the bioink may stimulate osteoclastogenesis to some degree, albeit that 
the number of soluble OPG molecules (60kDa) still exceeds the number of soluble 
RANKL molecules (32 kDa) by ~5-fold even in the presence of constructs containing 
vitD3. In addition, our assays did not allow us to establish changes in membrane-bound 
RANKL, e.g. as a result of shedding. Future osteoblast-mediated osteoclastogenesis 
experiments may reveal to what extent scaffolds made of our bioink modulate the 
formation, and activity, of osteoclasts.
IL-6 is a dual-edged cytokine that can play a role in osteogenesis, by enhancing 
differentiation of osteoblasts, upregulating ALP, and bone matrix formation [27,28], 
and play a role in osteoclastogenesis by upregulating RANKL [27,29]. Our results show 
that the released IL-6 increases in time, especially in the medium taken from cells 
cultured in the presence of constructs made of the bioink. At day 7, the amount of 
IL-6 released by cells cultured together with a construct with vitD3 was significantly 
higher compared to the amount released at day 0 and day 2 and the amount of IL-6 
released by cells cultured together with a construct without vitD3 was significantly 
higher at day 7 compared to all other time points. IL-6 can stimulate the first stages of 
osteogenic differentiation of osteoblast precursor cells [27], indicating that the bioink 
might induce osteogenic differentiation by inducing IL-6 release by osteoblasts in the 
vicinity. On the other hand, it may serve to increase RANKL expression and thereby 
osteoclastogenesis, although the conditions and time points that showed the highest 
IL-6 expression by U2OS cells did not correspond to the conditions and time points 
showing the highest RANKL expression. Finally, once implanted in vivo, cells in and 
near the constructs will be exposed to a cocktail of cytokines produced as part of the 
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wound healing process. More research is needed on the effect of our bioink on the 
osteogenic and osteoclastogenic differentiation of mesenchymal stem cells before 
we can conclude whether our construct will positively affect bone formation and 
remodeling. So far, we have no indication that the construct will negatively affect 
these processes in any way.
To have clinical potential, other aspects such as upscaling of production, the possibility 
to sterilize, and storage of preprinted materials should be considered. The printability 
of larger constructs made of CaP paste and κ-carrageenan needs to be tested. The 
gel is relatively pliable before crosslinking so special care should be taken to maintain 
the desired shape and porosity. Also, the storage of 3D-printed constructs needs to 
be considered. As the bioink is partly consisting of a gel structure it is not possible to 
store 3D-printed constructs in a dry environment because the construct will dry out 
and shrink. Storage in a wet environment such as PBS or SBF is possible, but when 
the material is enhanced with biological components, such as the vitD3 as used in the 
current study, part of the biological component would already be released and lost. 
For this reason, it would be optimal to directly place the construct after printing. We 
now only tested the reaction of cells that were not in direct contact with constructs 
made with the bioink, because we wished to determine the effect of the bioink on 
cells surrounding the ‘scaffold’ first. It is also important that stem cells recruited to the 
defect are able to attach to the material, but others have shown that several cell types 
are capable of attaching to precipitated CaP and κ-carrageenan.
In conclusion, constructs made of a bioink consisting of a combination of CaP paste 
and 3.8% κ-carrageenan, enhanced with vitD3, are relatively easy to handle, are 
bioactive, and are not cytotoxic to cells in the direct vicinity, paving the way for further 
development in order to create personalized 3D-printed scaffolds suitable for use in 
tissue engineering of large bone defects.
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The main objective of this thesis was to develop a method to 3D-print calcium 
phosphate combined with biological components that are released from the construct 
while retaining their biological activity, in order to enable or accelerate bone healing.
The ‘ideal’ tissue engineering construct
In tissue engineering, biomaterials, the type of cells required for the specific approach, 
and chemical and/or mechanical stimuli, are usually combined to generate a construct. 
Regarding the construct, according to literature the ‘ideal’ biomaterial for bone 
tissue engineering should have the following properties: biocompatible or bioinert, 
biodegradable, both osteoconductive and osteoinductive, porous, and mechanically 
compatible with native bone. Currently, most developed biomaterials only have some, 
but never all of these required properties [1–3]. In this final chapter, I will discuss how 
the current thesis contributes to the making of the ‘ideal’ bone tissue engineering 
construct.
Biocompatibility
Biocompatibility is the ability of a material to be placed in contact with human tissues 
without causing an unacceptable reaction of the body [4]. Natural polymers that 
are biocompatible and often used as biomaterials are collagen, gelatin, or chitosan 
[5]. Synthetic polymers that are generally considered to be biocompatible are e.g. 
poly-L-lactic acid (PLLA) and polycaprolactone diol (PCL)[6]. In this thesis, we used a 
printable material or bioink consisting of a combination of calcium phosphate and 
κ-carrageenan. Calcium phosphates are widely accepted to be biocompatible, and 
κ-carrageenan, which resembles glycosaminoglycans (GAGs), is used in the food 
industry and therefore can be considered as a bio acceptable material. Popa et al. 
studied both the in vitro and in vivo biocompatibility of κ-carrageenan hydrogels and 
showed a slightly lower metabolic activity in a cultured mouse fibroblast cell line, and 
no production of reactive oxygen species. A low inflammatory response in vivo was 
observed by the presence of only PMNs [7]. Similarly, an acute inflammatory reaction, 
but not a systemic reaction, was found by Lim et al. when a scaffold made of gelatin 
and κ-carrageenan was implanted subcutaneously in rats [8]. This lack of a systemic 
inflammatory reaction when using κ-carrageenan indicates that the initial immune 
responses to k-carrageenan were transient. Also, as stated earlier, the desired cells, 
being bone cells that contribute to bone formation and cells that ultimately replace 
the carrier, were not taken into account. We expected no, or very low, adverse effect 
of our bioink on cells. In chapter 5 we measured metabolic activity and cytotoxicity 
of U2OS cells co-cultured with constructs made of our bioink. The metabolic activity 
of cells cultured together with a construct is significantly lower than cells cultured on 
tissue culture plastic, but adding vitD3 to the bioink cancels this effect. The cytotoxicity 
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seems higher in the condition with only the bioink, although this is not significant 
compared to tissue culture plastic. Again, adding vitD3 reduced the cytotoxicity. This 
indicates that the bioink alone elicits a low cellular response, which is canceled by the 
addition of vitD3. This low response by the bioink might be improved by adjustments 
to the material.
Tissue engineering constructs based on materials normally present in the damaged 
human tissue that needs to be repaired have a good chance of being biocompatible. 
Several types of collagen are present in bone i.e. type I, III, and V, with collagen type 
I being the most abundant, comprising 90% of all organic matrix inside bone [9]. To 
better mimic the extracellular matrix of bone, collagen type I could be incorporated 
into the bioink or used as a coating. By adding collagen type I, the biocompatibility 
might be enhanced as collagen contains RGD binding sites to which cells can attach. 
We used κ-carrageenan instead of collagen because κ-carrageenan is derived from red 
seaweed that is abundantly available and it is much cheaper than collagen. Another 
adjustment that may improve the biocompatibility and cell attachment of the bioink 
is adding small (micrometers) CaP particles, made of the same precipitated CaP as 
the CaP paste used in the bioink. We have unpublished data that printing a bioink 
with CaP particles is possible. By adding such particles the surface roughness is likely 
to increase, which might enhance cell attachment [10]. With every adjustment to the 
material, the printability must be tested and the 3D-printing parameters optimized.
Biodegradable
Besides being biocompatible, the material should ideally also be biodegradable or 
at least bioinert. Biomaterials are often not intended to be permanent [11] because 
in time materials are affected by wear/fatigue, and cannot remodel, regenerate and 
adapt, while natural bone can. For these reasons it is preferred that bone will replace 
the biomaterial. Preferably, the material should be resorbed/dissolve at the same 
speed as new bone is formed.
Our bioink consists of precipitated calcium phosphate and κ-carrageenan. Calcium 
and phosphate ions affect bone resorption as calcium ions regulate the formation 
of osteoclasts [12], while phosphate ions inhibit bone resorption by interfering with 
RANKL signaling, thereby inhibiting osteoclast differentiation [13]. Liu et al. showed 
that precipitated CaP (similar to the protocol we used) is resorbed by osteoclasts in 
vitro [14]. This indicates that the CaP in our bioink might also be resorbed. However, we 
used a CaP paste instead of dried particles, therefore it is necessary to experimentally 
assess whether osteoclasts also absorb CaP paste. Κ-carrageenan is a naturally derived 
sulfated polysaccharide just like alginate. Alginate is derived from brown seaweed and 
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is known for its biocompatibility and biodegradation [15]. Alginate and κ-carrageenan 
can be enzymatically degraded; however, such enzymes are not present in humans. 
An ionically crosslinked alginate can be dissolved by the release of the ions that 
crosslink the gel in the surrounding medium [16]. Furthermore, the degradation of 
alginate depends on the pH. In an acidic environment of pH <5 the glycosidic bonds 
are degraded by acid hydrolyze [17]. Based on the similarity in molecular basis and 
origin, we suspect that κ-carrageenan undergoes a similar degradation process as 
alginate. Popa et al. show that κ-carrageenan hydrogels were degraded after 15 
days when placed subcutaneously in rats [7]. Taken together, we assume that our 
bioink, consisting of CaP paste and κ-carrageenan, is biodegradable. Whether this 
is indeed the case needs to be tested, as well as the degradation kinetics. Firstly, the 
rate of dissolving CaP can be tested in vitro. Preliminary tests (not shown) showed 
that a porous construct printed with CaP paste and 2.8% κ-carrageenan retained its 
shape for 7 days in phosphate-buffered saline. In other words, without the cellular 
component, at neutral pH and room temperature, these constructs are stable for at 
least multiple days. Further testing with 3.8% κ-carrageenan and other solvents such 
as simulated body fluid and culture medium would give a better understanding on the 
biodegradation of the construct. To assess whether cells resorb the bioink, experiments 
with cultured osteoclasts derived from human peripheral blood monocytes can used 
to give an indication.
Osteoconductive and osteoinductive
Osteoconductive materials are materials with a surface that permits the migration and 
growth of bone, while osteoinductive materials stimulate (stem) cells to differentiate 
into bone-forming cells [18,19]. To be effective, a tissue-engineered scaffold should be 
both, since both are needed for rapid bone formation throughout the construct and 
bone integration. For effective osteoconduction the scaffolds should fit the defect 
perfectly, thus facilitating the migration of cells from the adjacent bony environment. 
Therefore, 3D-printing is an appropriate production method, as it allows the creation 
of a custom-made scaffold to fit an individual defect e.g. based on CT scans.
Calcium phosphate-based materials are osteoconductive, and when CaP dissolves, 
calcium and phosphate ions are released. Calcium ions can influence bone formation 
and maturation through calcification [13]. Furthermore, these ions have an effect on 
bone regeneration as they stimulate mature bone cells and induce the proliferation 
of bone precursor cells [20]. Phosphate ions can also influence bone formation by 
regulating the differentiation and growth of osteoblasts and it increases the expression 
of BMPs [21].
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In chapter 5, we have performed preliminary tests for the ability of our bioink to 
enhance osteogenic differentiation in U2OS cells. The bioink did not affect ALP 
expression, however, the bioink upregulated Osteopontin (OPN) release. As U2OS cells 
are already considered osteoblast-derived cells, this is not osteoinduction in its purest 
form, but it is still indicative of a positive effect on osteogenic differentiation since 
the balance contributing to osteoclast differentiation. Furthermore, we have tested 
the influence of the bioink on cells that were not in direct contact with the material. 
After more in vitro tests, in vivo testing of the material is needed to really state if the 
material is both osteoconductive and osteoinductive.
The possibility to enhance the print material with biological components (such as 
vitD3) makes it suitable to improve osteoinductive properties with bioactive factors. 
Besides the often-used factors, BMP-2 and vitD3 other factors such as cytokines might 
be useful. In the first 72 hours of bone fracture healing, several cytokines are released 
such as TNF-α, IL-4, and IL-6. Especially, IL-6 might be of interest, as IL-6 stimulates the 
osteogenic differentiation of MSCs [22] and stimulates the formation of osteoclasts, 
thereby aiding the degradation of the scaffold material. However, dose and timing 
need to be very precisely tuned when using cytokines, since prolonged exposure to 
cytokines are generally catabolic, where short exposures are more likely to be anabolic.
In the study by Kuttappan et al. a combination of factors (VEGF, FGF, and BMP-2) was 
released from nanocomposite fibrous scaffolds. The factors were released at different 
time intervals and led to increased bone formation and vascularization [23]. This 
indicates that enhancing our material with a combination of factors might be the 
direction in which future research should be perused, although such a strategy can 
become costly, as some biological components are very expensive for applications 
in large defects. Furthermore, the optimal release kinetics will be component-
dependent, and overstimulation can lead to substantial side effects, such as ectopic 
bone formation and highly active osteoclasts caused by the BMP-2 [24], and growth 
inhibition when supraphysiological concentrations of vitD3 are used [25]. Finding the 
optimal release of a cocktail of components is more difficult and might lead to more 
side effects.
In chapter 2, we aimed to study which release kinetics of vitD3 is more optimal for 
osteogenic differentiation of adipose stem cells in vitro. We showed that a sustained 
release of vitD3 is more optimal for the osteogenic differentiation of adipose stem cells 
[26]. Our regime of 10 nM of vitD3 for 20 days highly upregulated the expression of 
Cyp24a1, which converts the active form of vitD3 to an inactive form [27]. We suspect 
that by using lower concentrations of vitD3 the mentioned upregulation will be less, 
6
559887-L-bw-Kelder
Processed on: 6-5-2021 PDF page: 120
120
Chapter 6
potentially leading to better osteogenic differentiation, which is preferable for bone 
tissue engineering. Unfortunately, we did not measure late osteogenic differentiation 
markers such as OPN, Dental Matrix protein-1 (DMP-1), and Actin alpha 1 (ACTA1). 
Assessing the expression of these components is recommended as differentiation 
towards the later stages of osteogenic differentiation are needed to form bone [28]. 
The experiments performed in chapter 2 are executed in vitro and were precisely 
controlled. To make tissue engineering constructs that release biological components 
in such a precise manner is difficult, and most materials first release a burst before 
having a sustained release. It would be interesting to test in vitro whether a combination 
of a burst with a sustained release is more optimal for osteogenic differentiation than 
the sustained release alone. Biologically this might make sense, as the initial burst may 
prime the surrounding cells to differentiate towards the osteogenic lineage. Overman 
et al. show that a 15-minute treatment of BMP-2 can already prime cells towards the 
osteogenic lineage. The sustained release can further differentiate the cells and also 
differentiate possible recruited stem cells towards the osteogenic lineage.
In chapters 3 and 5, we cultured cells in 2D. The advantage of 2D culturing is higher 
throughput and microscopical and biochemical analyses are easier. However, it 
is known that 2D culture does not fully mimic the in vivo environment, as it lacks 
cell-cell interactions from all sites and provides a different mechanical environment. 
Furthermore, many cell types, when cultured in 2D, become flattened and lose their 
differentiated phenotype [29]. Based on the study of Xiao et al. alveolar bone cells 
maintain their osteogenic properties more when cultured in a 3D environment [30]. 
This suggests the results we see in chapter 3 for alveolar bone cells might be different 
when performed in 3D, however, this might also be the case for long bone cells. We 
suspect that the results we see in our 2D studies will be more pronounced when it 
would be conducted in 3D. Taken together our bioink, with the vitD3 concentration we 
used only seems to have a slight osteogenic effect on U2OS cells. To really assess the 
osteoinduction properties of the bioink more studies, such as differentiation studies 
with stem cells, are needed.
Porous
Scaffolds for tissue engineering should have a porous structure as this is essential 
for the exchange of nutrients, proliferation, and migration of cells for vascularization 
and tissue formation [31]. It is especially important for large constructs to have 
interconnected pores, to allow for cell migration throughout the construct, and to 
allow rapid invasion of the construct with blood vessels to ensure oxygen delivery 
inside the complete construct, including the (often severely hypoxic) center. The 
ideal pore size for bone tissue engineering is not completely clear but is estimated 
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to range between 100-1000 µm [32]. The minimal scaffold pore size for cell migration 
and exchange of nutrients has been claimed to be 100 µm, but other studies show 
that pores above 200 µm promote deep vascularization [33].
In chapter 4 and 5 we used 3D-printing to design and create constructs with a pre-
defined internal structure. By using 3D-printing, we created constructs with pores of 
approximately 2.2 mm3 with 3.8% κ-carrageenan. These pores are large enough for 
angiogenesis and bone ingrowth [34]. Unfortunately, these pores are only one way 
(vertically) and not interconnected which would be preferable. This is the result of the 
viscosity of the material which causes it to spread when printed on a surface and is 
not strong enough to stack the layers and create interconnected pores. To overcome 
this, embedded printing methods can be used, where the bioink is extruded in a 
supporting material such as a hydrophobic high-density fluid [35–37]. Indirect printing 
is another way to make interconnected pores. With this method, a sacrificial mold is 
created, followed by casting the scaffold material in the mold and then removal of the 
mold [38,39]. We did some tests with this method; however, we encountered some 
obstacles such as removing the mold without breaking the printed construct. One 
more way to create interconnected pores with our bioink is printing simultaneously 
with sacrificial material. By removing the sacrificial material pores are created. The 
sacrificial material would preferably dissolve when the bioink is crosslinked or washed. 
Extensive steps to dissolve the sacrificial material are likely to affect the activity of 
the incorporated bioactive factors and are therefore undesirable. The ready-to-print 
sacrificial and support ink of Cellink (commercially available) might be a good option 
to use.
Mechanically compatible with native bone
Materials have different mechanical properties such as the stiffness of the material 
which cells feel, or the mechanical properties of the bulk of the material made into 
a scaffold. When it is proposed that an ideal tissue engineering construct should be 
mechanically compatible with the native bone it suggests that the bulk mechanical 
properties should be in the same range and therefore can carry some load. The 
material should not be too stiff as this will lead to stress shielding [40], a phenomenon 
characterized by the reduction of bone density as a result of the removal of mechanical 
load from the bone by the material. In chapter 5, we show that mechanically, our print 
material is not in the range of native bone, namely the compression modulus of our 
bioink is ~10.000 times lower. For the use in non-load defects such as the sinus floor 
elevation, this is less important and load-bearing defects can initially be stabilized 
with screws. However, there are some options to try and improve the mechanical 
properties of our print material. First of all, adding small CaP particles or rods to the 
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mixture of paste and κ-carrageenan. In the study of Nejati et al. both precipitated rods 
as commercially bought particles were added to PLLA scaffolds and both improved 
the mechanical properties compared to PLLA alone [41]. Another method to improve 
the mechanical properties can be to alternatingly print strands of our print material 
between strands of a biodegradable polymer such as PLGA or PCL [42]. The mechanical 
properties of such polymers are higher and can work as a sort of cage to protect the 
softer print material against mechanical loading. A downside is that less bioink is used 
to create a scaffold and the amount of biological component should be adjusted to 
the lesser amount of bioink.
Other properties
The above-discussed properties are the classical properties needed for the ‘ideal’ 
tissue engineering construct. Other properties that are useful to consider or needed 
such as vascularization. Vascularization is crucial in tissue engineering and therefore 
scaffolds should induce angiogenesis [43]. One of the most used factors to induce 
vascularization is VEGF as it promotes the first phases of angiogenesis such as 
endothelial cell sprouting. Other factors such as ANG1 can be used or a combination 
of VEGF and ANG1 as the angiopoietin–Tie signaling system seems to complement 
the VEGF pathway [44,45].
In addition, there are probably no uniform solutions for all bone defects. In chapter 
3, we aimed to study if skeletal sites react differently to possible cues from such tissue 
engineering constructs. We did this by comparing cells derived from human alveolar 
bone with cells derived from human long bone when studying their osteogenic and 
osteoclastogenic potential with and without vitD3. Our results showed that cells from 
different skeletal sites have site-specific differences. Cells derived from long bone are 
more differentiated within the osteogenic lineage, while alveolar bone cells proliferate 
faster. Furthermore, long bone cells have increased osteoclastogenic potential 
compared to alveolar bone cells [46]. These differences indicate that the ‘ideal’ tissue 
engineering construct should take the site of an implant into account.
To be clinically applicable, other properties such as sterilizability, costs, shelf life, and 
production time need to be considered.
Taken together, did we make the ideal bone tissue engineering construct suitable for 
each site? No, we are not there yet. However, we did lay a firm foundation for a bioink 
that might have the potential to be optimized and used for bone tissue engineering.
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Chapter 7
Bone defects can arise as a consequence of trauma, cancer, inflammation, or 
overloading. Even though natural bone has good intrinsic healing capacity, the 
reconstruction of critical size bone defects remains a challenge. Currently, the “golden 
standard” for this type of defects is the use of autologous bone grafts. These grafts 
are taken from the patient, often from the iliac crest, or in the case of orofacial defects 
from the symphysis of the chin or ascending ramus. Autologous bone grafts provide 
both an osteoconductive and osteogenic environment, as a result of the presence of 
living cells and the cocktail of growth factors in the matrix. This method, however, has 
major drawbacks: bone grafts are only available in limited volumes and this procedure 
can cause long-lasting donor site morbidity and pain. These drawbacks could be 
overcome by alternative approaches for bone reconstruction, such as methods 
employing principles of bone tissue engineering, combining scaffolds, cells, and/or 
chemical stimuli.
Biological components such as growth factors and cytokines can be used as 
chemical stimuli aiding bone tissue engineering. The kinetics of delivery of biological 
components will influence the biological effect of the component, or the occurrence 
of side effects. In chapter 2, we shed light on the continuing debate whether short, 
burst or sustained release is the best mechanism for the application of biological 
components for bone tissue engineering. We mimicked the in vivo situation in a 
cell culture environment by seeding human adipose stem cells (hASCs) on clinically 
applicable biphasic calcium phosphate (BCP) particles, allowing precise manipulation 
of doses and timing of application. We aimed to investigate which application of vitD3 
i.e. mimicking short exposure of cells ([200 nM] for 30 minutes), burst release from 
scaffolds ([100 nM] for 2 days), or sustained release from scaffolds ([10 nM] for 20 
days), leads to optimal osteogenic differentiation of hASCs. Our results suggest that 
mimicking sustained release by delivery of a daily dose of vitD3 seems to have more 
effect on hASCs than the other applications. Delivery of vitD3 for a longer period did 
not lead to apoptosis and triggers ALP activity at day 7 and day 20. It also affected 
the gene expression of key osteogenesis regulator gene RUNX2, and genes involved 
in the vitD3 metabolism, VDR, and CYP24a1.
Bone tissue engineering constructs send signals to cells in the bone to form more bone 
and to recruit stem cells, which can differentiate into cells that form bone. Cells from 
different skeletal sites may react differently to such signals. Therefore, in chapter 3 we 
analyzed the degree of differentiation of bone cells derived from human long bone 
and alveolar bone. Furthermore, the production of signaling molecules by these cells 
and their capacity to induce osteoclast formation was measured in the presence or 
absence of biological component vitD3. The results show that under basic culturing 
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conditions long bone cells seemed more differentiated compared to alveolar bone 
cells. Furthermore, long bone-derived cells have stronger osteoclastogenic potential 
than alveolar bone cells. Taken together, these differences reveal that skeletal 
sites generate site-specific differences between the cells and indicate that for the 
regeneration of specific sites, such as the alveolar bone, more research on site-specific 
tissue engineering constructs is needed.
3D-printing can be used to make scaffolds for bone tissue engineering. By using 
this technique patient-specific scaffolds can be created that fits the defect perfectly. 
Calcium phosphates are often used in bone tissue engineering as it resembles 
the crystals of hydroxyapatite in bone. 3D printing of calcium phosphates with a 
chemical stimulus such as growth factors is a challenge since methods using high 
temperatures or aggressive chemicals, such as Selective laser sintering and 3D-powder 
printing, impede the bioactivity of the incorporated biological components. Cells 
and proteins that are active at body temperature lose their life or bioactivity at such 
high temperatures, or are denatured by the chemicals. In chapter 4, we developed 
a method to 3D print calcium phosphate with a biological binder allowing for the 
incorporation of biologically active components as chemical stimuli. We show that 
it is possible to 3D print with a mixture of precipitated calcium phosphate paste and 
κ-carrageenan. To show the ability to incorporate biological components BSA-FITC 
was used as a model. We show the incorporation of the BSA-FITC inside the print 
material and also show that the BSA-FITC is released, indicating that this method can 
be used to 3D print constructs with biological components. More research on the 
clinical relevance of this method is needed.
Finally, in chapter 5, as the next step towards a clinical application, we assessed 
if constructs printed with the method described in chapter 4, and enhanced with 
1,25(OH)2vitD3 as a biological component, can be clinically relevant. In order to meet 
clinical relevance, the material should have the following features: The material 
should have a certain rigidity, so the surgeon can handle the construct and it should 
be tolerated by cells, so no adverse body reaction takes place. We investigated these 
features by measuring the printability, compressive stiffness, and cytotoxicity of the 
material and the effect of the material on U2OS human osteosarcoma-derived cells 
when cultured in close proximity to the print material. The results show that the 
material is printable, is rigid enough to handle, and did not have an adverse effect 
on the proliferation of U2OS cells when co-cultured. We also showed that the vitD3 is 
released from the material, and most importantly, is bioactive.
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Taken together, the combined results in this thesis suggest that constructs made of 
CaP paste and κ-carrageenan could be clinically relevant and that 1,25(OH)2vitD3 could 
be a biological additive that enhances the osteoinductive potential of the construct. 
However, precise tuning of the release characteristics may be necessary to increase 
the effectivity 1,25(OH)2vitD3. In addition, when the construct is made for the purpose 
of healing large bone defects in the orofacial area, research into other osteoinductive 
components to enhance the construct may be necessary as alveolar bone cells are 
different and react differently to 1,25(OH)2vitD3 than long bone cells.
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Chapter 8
Botdefecten kunnen ontstaan als gevolg van onder andere trauma, kanker, 
ontsteking of overbelasting. Hoewel bot van nature goed geneest, blijft de 
reconstructie van botdefecten van kritische grootte (CSBD) een uitdaging. 
Momenteel is de “gouden standaard” om dit soort defecten te reconstrueren het 
gebruik van autologe bottransplantaties. Bot voor deze transplantaties wordt bij de 
patiënt zelf afgenomen, vaak van de bekkenkam en voor aangezichtsdefecten vanuit 
de kin of de ramus. Autologe bottransplantaties zorgen voor zowel een botgroei-
geleidende omgeving als een botvorming-inducerende omgeving, omdat het 
levende cellen bevat, alsmede een cocktail van groeifactoren in de extracellulaire 
matrix. Deze methode heeft echter grote nadelen: Bot voor de bottransplantaties 
is slechts in beperkte hoeveelheden beschikbaar, past meestal niet naadloos in het 
op te vullen defect, en het oogsten kan langdurige pijn veroorzaken. Deze nadelen 
kunnen worden overwonnen door alternatieve behandelmethoden te gebruiken, 
zoals tissue engineering, waarbij een combinatie van dragermaterialen (scaffolds), 
cellen, en/of chemische stimuli wordt gebruikt.
Biologische componenten zoals groeifactoren en cytokinen kunnen worden gebruikt 
als chemische stimuli om botweefsel vorming te ondersteunen. De kinetiek van afgifte 
van biologische componenten, uit bijvoorbeeld een dragermateriaal, kan het effect 
van de betreffende component, of het optreden van bijwerkingen beïnvloeden. In 
hoofdstuk 2 werpen we licht op de voortgaande discussie of een piek, kortstondige, 
of langdurige afgifte van biologische componenten vanuit dragermaterialen, specifiek 
gebouwd voor botweefsel tissue engineering, botgroei het meest stimuleert. We 
hebben daarvoor de in vivo situatie gedeeltelijk nagebootst in een celkweekomgeving. 
Dit hebben we gedaan door menselijke stamcellen verkregen uit vetweefsel 
(hASC’s) op klinisch toepasbare calciumfosfaat deeltjes te zaaien, waardoor een 
nauwkeurige manipulatie van de dosering en timing van afgifte van de onderzochte 
componenten mogelijk is. Ons doel was om te onderzoeken welke toediening van 
1,25(OH)2vitamineD3 (vitD3) leidt tot een optimale osteogene differentiatie van hASCs. 
We hebben gekozen voor het nabootsen van de volgende situaties: een zeer korte 
blootstelling van cellen aan vitD3 ([200 nM] gedurende 30 minuten), het kortstondig 
toevoegen van vitD3 ([100 nM] gedurende 2 dagen), of het langdurig toevoegen van 
vitD3 ([10 nM] gedurende 20 dagen). Onze resultaten suggereren dat het nabootsen 
van langdurige afgifte, door het toedienen van een dagelijkse dosis vitD3, meer effect 
lijkt te hebben op de osteogene differentiatie van hASC’s dan de kortere toepassingen. 
Het toedienen van vitD3 voor een langere periode leidde niet tot apoptose en 
stimuleert de ALP-activiteit op dag 7 en dag 20. Daarnaast beïnvloedde het ook de 
genexpressie RUNX2, een belangrijke regulator voor osteogenese, en de genen die 
betrokken zijn bij het vitD3-metabolisme, VDR en CYP24a1.
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Constructen die geschikt zijn voor bot tissue engineering sturen signalen naar cellen 
in het bot om meer bot te vormen en om stamcellen aan te trekken. Deze stamcellen 
kunnen vervolgens 120 differentiëren in cellen die botmatrix vormen. Cellen van 
verschillende plekken in het skelet kunnen echter mogelijk verschillend reageren 
op signalen afkomstig van tissue engineering constructen. Daarom hebben we in 
hoofdstuk 3 de respons van mesenchymale botcellen (osteoblasten) afkomstig 
van menselijke pijpbeenderen en alveolair bot op biologische componenten 
geanalyseerd. Daarnaast hebben we de productie van signaalmoleculen door deze 
cellen gemeten, alsmede hun vermogen om osteoclast vorming te induceren in de 
aanwezigheid of afwezigheid van vitD3. De resultaten tonen aan dat onder standaard 
celkweekcondities cellen van pijpbeen meer gedifferentieerd leken dan alveolaire 
botcellen. Bovendien hebben pijpbeencellen een sterker osteoclastogeen potentieel 
dan alveolaire botcellen. Samen laten deze verschillen zien dat de locatie van het bot 
in het skelet voor specifieke verschillen tussen de cellen zorgt. Dit geeft aan dat voor 
de regeneratie van specifieke locaties, zoals het alveolaire bot, meer onderzoek nodig 
is naar locatie-specifieke tissue-engineering constructen.
3D-printing kan worden gebruikt om scaffolds te maken voor botweefsel engineering. 
Door gebruik te maken van deze techniek kunnen patiënt-specifieke scaffolds worden 
gemaakt die perfect passen in het defect. Calciumfosfaten worden vaak gebruikt voor 
bot tissue engineering omdat deze in samenstelling lijken op het hydroxyapatiet in 
bot. Het 3D printen van calciumfosfaten met daarin biologisch actieve factoren zoals 
groeifactoren is een uitdaging, omdat de meeste gangbare 3D print-methoden gebruik 
maken van hoge temperaturen of agressieve chemicaliën die de bioactiviteit van de 
geïncorporeerde biologische componenten negatief beïnvloeden. Cellen en eiwitten, 
die actief zijn bij lichaamstemperatuur, gaan dood of verliezen hun bioactiviteit 
bij zulke hoge temperaturen, of worden gedenatureerd door de chemicaliën. In 
hoofdstuk 4 hebben we een methode ontwikkeld om calciumfosfaat te 3D printen 
met een biologisch bindmiddel dat de opname van biologisch actieve componenten 
als chemische stimulans mogelijk maakt. De combinatie van calciumfosfaat en 
bindmiddel noemen wij een “bioinkt”. We laten zien dat het mogelijk is om een 3D 
construct te printen van een bioinkt bestaande uit neergeslagen calciumfosfaat, in de 
vorm van een pasta, en κ-carrageenan, een uit zeewier verkregen materiaal dat lijkt op 
de glycosaminoglycanen in extracellulaire matrix. Om de mogelijkheid om biologische 
componenten in te bouwen aan te tonen werd BSA-FITC aan de bioinkt toegevoegd. 
We tonen de integratie van de BSA-FITC in het printmateriaal aan, en laten ook zien dat 
de BSA-FITC vrijkomt na het printen. We laten zo zien dat deze methode kan worden 
gebruikt om 3D geprinte constructen met biologische componenten te maken. Echter, 
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of de biologische component nog bioactief is, is hiermee niet aangetoond, en meer 
onderzoek naar de klinische relevantie van deze methode is nodig. 
Als eerste stap naar een klinische toepassing hebben we tot slot in hoofdstuk 5, 
onderzocht of de constructen geprint met de methode beschreven in hoofdstuk 4, met 
vitD3 als biologische component, klinisch relevant kunnen zijn. Om aan de klinische 
relevantie te voldoen, moet het materiaal ten minste de volgende kenmerken hebben: 
Het materiaal moet een bepaalde mechanische stijfheid hebben, zodat het hanteerbar 
is, en het moet door de cellen worden getolereerd, zodat er geen bijwerkingen in het 
lichaam plaatsvinden. We hebben deze kenmerken onderzocht door de printbaarheid, 
de compressiestijfheid en de cytotoxiciteit van het materiaal te meten. Daarnaast 
hebben we het effect van het materiaal op menselijke osteoblast-achtige cellen (U2OS) 
getest wanneer deze worden gekweekt in de nabijheid van de bioinkt. De resultaten 
tonen aan dat het materiaal printbaar is, stijf genoeg is om voorzichtig vast te kunnen 
houden en geen nadelig effect heeft op de proliferatie van U2OS-cellen wanneer deze 
worden gekweekt in de nabijheid van de bioinkt. We hebben ook aangetoond dat 
de vitD3 uit het materiaal vrijkomt, en het belangrijkste is dat het vitD3 nog bioactief 
is als het vrijkomt.
De gecombineerde resultaten in dit proefschrift suggereren dat constructen 
gemaakt van CaPpasta en κ-carrageenan klinisch relevant zouden kunnen zijn, en 
dat 1,25(OH)2vitD3 een biologisch additief zou kunnen zijn dat het osteo- inductief 
potentieel van het construct versterkt. Een nauwkeurige afstemming van de afgifte 
kan echter nodig zijn om de effectiviteit van vitD3 te verhogen. Bovendien kan, 
wanneer het construct is gemaakt voor het genezen van grote botdefecten in het 
orofaciale gebied, onderzoek naar andere osteo-inductieve componenten nodig zijn 
om het construct te verbeteren, omdat alveolaire botcellen anders zijn en anders 
reageren op vitD3 dan pijpbeen cellen.
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Het moment is daar! Ik ben aan het einde van een spannend en uitdagend hoofdstuk 
uit mijn leven, en uitdagend is het geweest. Daarom ben ik alleen maar trotser dat ik het 
einde heb gehaald en mijn PhD kan afronden. Ik had dit niet alleen gekund en wil mijn 
dankbaarheid tonen aan iedereen die mij heeft geïnspireerd, geholpen en gesteund.
Allereerst wil ik prof.dr. Daniel Wismeijer en prof.dr. Jenneke Klein Nulend 
bedanken voor de geweldige kans die ze mij hebben gegeven om dit PhD project 
te mogen doen. Daarnaast wil ik jullie beide bedanken voor alle feedback om mijn 
artikelen zo goed mogelijk te maken.
Dr. Astrid Bakker, beste Astrid, ik wil je bedanken dat je mijn begeleiding hebt 
overgenomen. Jouw kennis en kunde is heel motiverend. Ook wil ik je bedanken 
voor het pushen, het beste uit mijzelf te halen, maar ook voor de bemoedigende 
woorden wanneer ik het zwaar had. Je bent een voorbeeld voor mij en ik hoop dat 
we contact houden.
Dr.ir. Teun de Vries, beste Teun, jij hebt mij onder je vleugels genomen toen ik dat het 
hardst nodig had. Onze experimenten samen in het lab waren leerzaam en gezellig. 
Dat ik nog vaak dansjes mag doen die jij dan nadoet!
prof.dr. Cees Kleverlaan, beste Cees, bedankt dat jij geholpen hebt om mijn project 
weer op de rit te krijgen en voor alle steun op de juiste momenten.
I want to thank the committee members for the time they spent on reading my thesis. 
It is an honor to have you at my defense ceremony.
In het bijzonder wil ik mijn paranimfen Jolanda en Wessel bedanken. Lieve Jolanda, na 
het eerste jaar werd jij aan mij gekoppeld en sindsdien waren we labmaatjes. Jij hebt mij 
door dik en dun gesteund (met en zonder prosecco) en jouw hulp was van onschatbare 
waarde. Bedankt voor alles wat je hebt gedaan en voor de leuke borrels. Dat we nog 
heel lang samen bubbels mogen drinken. Lieve Wessel, bedankt! Volgens jou was dit 
genoeg maar dat vind ik niet. Ik ben heel blij dat jij naast mij staat bij deze belangrijke 
gebeurtenis want jij bent mijn belangrijkste steunpilaar buiten ACTA geweest. Ik kon 
altijd bij je terecht en jij hebt altijd in mij gelooft ook wanneer ik dat zelf soms niet deed. 
Bedankt voor alle filmavonden met hele slechte films en veel sniper.
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Ik wil ook het geweldige ondersteuningsteam van de 11e verdieping bedanken. Cor, 
bedankt voor al je hulp! Ook al wist je helemaal niets ;). Marion jij bent de stille kracht 
op de afdeling. Jolanda, zonder jouw geweldige lach zou niemand weten dat er een 
11de verdieping bestond. Ton, bedankt voor al je advies tijdens de lekkere biertjes en 
je bent zooo grappig ;). Behrouz, jij bent een wandelende encyclopedie.
Daarnaast wil ik mijn PhD maatjes Carolyn, Tijmen, Ursula en Yvon bedanken. Lieve 
Carolyn, jij bent een geweldig voorbeeld voor mij geweest en ik wil je bedanken 
voor alle lieve steun die jij mij hebt gegeven. Jij wist precies waar ik soms doorheen 
ging en was niet bang om dit te delen, daar ben ik je heel dankbaar voor. Ook onze 
shoppinguitjes en lunchdates nadat we weer in het weekend moesten werken zal 
ik missen. Ik ben super dankbaar voor de mooie vriendschap die is ontstaan. Beste 
Tijmen, mijn mede biomedical engineer, bedankt voor alle sparringrondes en theetjes, 
die heb ik altijd erg gewaardeerd. Ook bedankt voor de toffe tijd in Athene, mijn 
voeten doen nog steeds pijn van al het lopen. Ik zal alle leuke borrels en onze ‘inside’ 
nerd grapjes, die alleen wij snapten, missen. Dear Ursula, my sweet Brazilian girl, thank 
you for all your support and pep talks while eating Kinder chocolate. Lieve Yvon, ook al 
was je niet de hele week op ACTA ik kon altijd bij je terecht. Bedankt voor de gezellige 
theetjes, etentjes en het verven van mijn haar.
I want to thank my sweet roomies for all the great times, but also support in the more 
difficult times. You all believed in me! Ivana, you are such a great woman and scientist. 
Thanks for all your advice, nice talks and our squat moments. I wish you a lovely future 
with Ivan and your daughter Jana. Dear Silvia, your enthusiasm for research has been 
an inspiration. I have happy memories of our trip to Paris and Disneyland! Thanks for 
all the support. Dear Yasaman, Thanks you for your positive vibes and help with the 
3D printer. Dear Jiayi, no wonder we can call you Joy. You are always so joyful and 
positive. Thank you for all the nice talks and hugs. And last but not least: dear Behrouz, 
mijn ‘zeer gewaardeerde collega’ you are one of the nicest persons I have ever met 
and you are always willing to help. Thanks for everything!
Ik heb zelf geen studenten begeleid, maar er waren studenten op de afdeling waarmee 
ik wel een goede band heb opgebouwd. Fenne, bedankt voor alle leuke ‘theetijd’ 
en Disney-films. Nog heel veel succes met het afronden van je eigen PhD. Yanaika, 
bedankt voor alle gezellige treinritjes, ik ga ze echt missen! Hanneke, bedankt voor 
alle fijne gesprekken en steun in de moeilijke tijden.
Ik wil alle (oud) collega’s van de 11de en 12de verdieping bedanken: Ineke, Jinfeng, 
Dagmar, Vivian, Wei, Mingjie, Angela, Fereshteh, Clara, Tineke, Jan-Harm, Hans, 
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Kamran, Toon, Wendy, Sara, Beatriz, Sophie, Marieke en Victor. Heel erg bedankt 
voor alle gezelligheid, borrels en lunches, maar ook voor de feedback en steun! En 
Victor, hierbij geef ik mijn vloek over aan jou!
Ook wil ik de mensen van de afdeling implantologie bedanken en dan in het bijzonder 
Nawal, voor het wegwijs maken met de 3D printer en Gang, voor het protocol van 
de calciumfosfaat productie.
Ik wil graag mijn lieve vrienden bedanken voor alle gezellige avonden, uitjes, drankjes 
en festivals. Deze afleidingen waren van cruciaal belang! Lieve Suus, bedankt dat 
ik onderdeel van jullie meubilair mag zijn en ik altijd bij je terecht kan. Je wist vaak 
de juiste vragen te stellen waardoor ik tot inzicht en tot rust kwam. Beste Kevin, 
jij wist maar al te goed dat je niet altijd naar mijn PhD moest vragen en ik kon 
altijd bij je terecht als ik er even uit moest! Jammer dat we uiteindelijk niet hebben 
kunnen samenwerken. Lieve Yvette, bedankt voor de gezellige avonden en de 
leuke telefoongesprekken. Lieve Femke, met jou kon ik altijd mijn gedachten even 
verzetten, met Mario karten en drankjes. We moeten zeker nog een keer touren door 
’t gooi. Beste Pascal, ik wil je bedanken voor jouw hulp en steun tijdens mijn bachelor, 
(pre)-master en het eerste deel van mijn PhD.
Girls: Rosalie, Lisa en Anne-Sophie, mijn heksjes, onze meidenavonden met 
spelletjes, maskers en veel chocola waren altijd een goede afleiding. Bedankt voor 
jullie steun! Jullie zijn geweldig!
Lieve Margo, ook al zien we elkaar niet heel vaak zodra we weer samen zijn is het 
alsof we elkaar nog steeds elke dag zien! Ons jaarlijkse uitje naar de Zwarte Cross is 
geweldig en ik kijk er altijd naar uit. Ik hoef je maar te bellen en je staat voor mij klaar, 
bedankt voor al je steun.
Lieve Rosa, Ik ben zo blij dat ik zo’n leuke vriendin in Hilversum heb. Bedankt voor 
alle wijntjes en onze heerlijke wandelingen. Hopelijk kunnen we snel weer naar leuke 
festivals. Lieve Ashley, vanaf het eerste moment op het vliegveld naar Bali hadden wij 
een klik. Thanks voor alle leuke dagjes uit en alle steun. Ik kan altijd mijn verhaal bij je 
kwijt. De rest van de balichicks: Stephanie, Gea en Liza, onze uitjes waren altijd erg 
gezellig en een fijne afleiding. Jullie waren altijd geïnteresseerd en probeerden mij te 
helpen. Op naar het volgende uitje!
Als laatste wil ik mijn lieve familie bedanken. Jullie hebben altijd in mij geloofd en 
mij enorm gesteund. Lieve Angelique en Milo, Ik kan jullie altijd bellen en jullie 
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hebben mij veel gesteund op de momenten dat ik het moeilijk had. Bedankt! Lieve 
Martinke, mijn grote zus, bedankt voor al je liefde en vertrouwen in mij. Lieve pap 
en mam, bedankt voor jullie onvoorwaardelijke steun en liefde. Jullie hebben mij 
altijd gestimuleerd om te doen wat ik graag wilde en er het beste uit te halen. Dit is 
het mooie resultaat!
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